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Abstract
A num ber of peptide fragments including (2S)-Pro-(2S)-Ile-NHiBu (72) and 
(2S)-Phe-(2S)-Ile-NHiBu (73) and l-(benzyloxycarbonyl)-aminophosphinic acid 
m ethyl esters (analogues of Phe (76), Cha (77) and Leu (78)) have been 
synthesised and coupled to give a series of phosphonamidate methyl ester-based 
peptide inhibitors of HIV-1 proteinase. These compounds were tested against the 
proteinase enzyme in vitro using a spectrophotometric assay and displayed 
activities in the 1-100 pM range. Remarkably, comparison of these data with data 
obtained for activities against HIV-1 in cultured human lymphocytes showed an 
in vitro'.in vivo ratio of approximately 1:1. These results are indicative of a 
highly efficient cell uptake mechanism and exceed the reported in vitroiin vivo 
ratios for HIV proteinase inhibitors by a factor of 10 .^ It is also apparent from the 
results that the compounds are not rapidly degraded in hum an lymphocytes. # 
The activities of these compounds, however, was rather insensitive to small 
s truc tu ra l changes, underm ining  our attem pts to optim ise them . A 
phosphonam idate ethyl ester (Cbz-Phe-PO(OCH2CH3)NH-(2S)-Phe-(2S)-Ile- 
NHiBu (94)) was prepared and this possessed an IC50 of 4.5 pM, indicating that it 
m ight be possible to incorporate larger ligands onto the ester portion of the 
molecule.
Due to the problems associated with peptidic compounds as therapeutic 
agents, a num ber of non-pep tid ic  targets w ere designed . 3,3'-Di- 
(benzyloxycarbonyl)-aminobenzoin (103) was synthesised in three steps from m- 
nitrobenzaldehyde and this displayed an IC50 of 8 pM.
Molecular modelling of a second target, a bicyclic phosphorodiamidate (106), 
show ed that this com pound should adopt a skewed position w ithin the 
enzyme's active site, with the OH group between the catalytic aspartates (Asp 25 
and Asp 25') and the P = 0 strongly hydrogen-bonded to one of the flap He's but 
relatively distant from the other. A synthesis of this molecule from tris 
(hydroxymethyl)amino-methane was undertaken, but problems with this led to 
the design of the less-substituted phosphorodiamidate (116). An alternative 
route from diethyl malonate was begun, although to date this has not been 
completed. This work is now under investigation by others in our group.
j
Contents
Page
Acknowledgements i
Abstract ii
List of figures V
List of schemes v i
List of tables v i
Abbreviations vii
Amino acid codes ix
1.0 Introduction. 1
1.1 General introduction. 1
1.2 The life and times of HIV. 1
1.3. The life cycle. 4
1.4 Therapeutic targets. 8
1.4.1 Reverse transcriptase. 8
1.4.2 Proteinase. 10
1.4.3 Glucosidase inhibitors. 11
1.4.4 Inhibitors of gene expression. 11
1.4.5 Viral binding inhibition. 12
1.4.6 Tat regulatory protein. 13
1.4.7 Other targets. 13
1.5 HIV-1 proteinase. 13
1.5.1 Classification. 14
,1.5.2 Preparation and purification. 15
1.5.3 Substrate specificity. 16
1.5.4 Structural properties of HIV-1 proteinase. 19
1.5.5 Catalytic mechanism. 23
111
.a
1.6 Proteinase inhibitors. 24
1.6.1 Reduced amides. 27
1.6.2 Phosphinic acids. 28
1.6.3 Statines. 29
1.6.4 Difluoroketones. 30
1.6.5 Hydroxyethylamines. 31
1.6.6 Hydroxyethylenes. 32
1.6.6.1 Modified hydroxyethylenes. 34
1.6.7 Ci-symmetric inhibitors. 35
1.6.7.1 Other C2-symmetric inhibitors.. 38
1.6.8 Non-peptides. 40
1.6.8.1 Natural products. 40
1.6.8.2 Heterocyclic inhibitors. 44
2.0 Results and discussion. 48
2.1 Design of HIV-1 proteinase inhibitors. 48
2.2 Synthesis and testing of phosphonamidate-based
inhibitors for HIV-1 proteinase. 51
2.2.1 Solution-phase peptide synthesis. 53
2.2.2 Synthesis of phosphinic acid esters. 54
2.2.3 In vitro testing. 58
2.2.4 Incorporation of piperidine-2-carboxylic acid. 65
2.2.5 Extending the chain. 68
2.3 Interlude - Benzoin inhibitors of HIV-1 proteinase. 72
2.4 Bicyclic phosphorodiamidates. 75
3.0 Experimental 88
4.0 References. 123
Appendix A 141
Appendix B 142
I V
List of Figures
Page
1.1 Schematic representation of HIV. 3
1.2 Diagram of the viral life cycle. 4
1.3 The HIV-1 genome. 6
1.4 Anti-sense oligonucleotides. 12
1.5 The gag, pol and env polyproteins. 17
1.6 Cleavage sites in HIV-1 proteinase. 17
1.7 The HIV-1 proteinase, 20
1.8 The 'Fireman's Grip'. 21
1.9 The mechanism of general acid-general base catalysis. 24
1.10 Transition state mimics. 25
1.11 Comparison of transition state mimics. 26
1.12 Design of C2-symmetric inhibitors.. 36
1.13 Symmetric and asymmetric binding in symmetric diols. 38
1.14 Axis C. 39
1.15 Tetronic acid homologues. 44
1.16 Cyclic ureas. 46
2.1 Comparison of tetrahedral intermediate and
phosphonamidate isostere. 48
2.2 Comparison of gem-diol and gem-diolate with 
phosphonamidate methyl ester and
phosphonamidate respectively. 49
2.3 Comparison of the relative charges on a
phosphonamidate methyl ester and a gem-dioL 50
2.4 McLeod et al.'s dipeptide inhibitors. 53
2.5 Lineweaver-burke double reciprocal plot for
phosphonamidate (79), 60
2.6 Some phosphonamidate methyl ester inhibitors. 61
2.7 Further phosphonamidate methyl ester inhibitors, 63
2.8 Plot of 1/initial rate against inhibitor concentration for
phosphonamidate (79). 64
2.9 Plot of 1 /initial rate against inhibitor concentration for
phosphonamidate (82), 65
2.10 Plot of 1/initial rate against inhibitor concentration for
phosphonamidate ethyl ester (94). 72
2.11 Enolisation of benzoin. 73
2.12 Plot of 1 / initial rate against inhibitor concentration for
benzoin (103). 75
2.13 Phosphorodiamidate (106) bound into the active site of
HIV-1 proteinase. 77
2.14 Phosphorodiamidate (106) bound into the active site of
HIV-1 proteinase (alternate view). 78
List of Schemes
2.1 Mechanism of mixed anhydride coupling. 53
2.2 Oxidation of amino-phosphonous acid to
amino-phosphinic acid. 55
2.3 Synthesis of phosphinic acid methyl ester. 56
2.4 Mechanism of formation of diphenyl phosphonate (74). 57
2.5 One-pot procedure for the synthesis of phosphinic acid
methyl esters. 58
2.6 Preparation of L-pipecolinic acid from L-lysine. 66
2.7 Resolution of D/L-pipecolinic acid using D-tartaric acid. 67
2.8 Attempted synthesis of trifluoroethoxy analogue (98). 70
2.9 Synthesis of Cbz-amino-phosphinic acid esters
via phosphonous acid. 71
2.10 Synthesis of benzoin (103). 73
2.11 Mechanism of benzoin condensation. 74
2.12 Proposed synthesis of phosphorodiamidate (106). 79
2.13 Preparation of dihydrazone (115). 81
2.14 Proposed route to simpler phosophorodiamidate ( l l 6). 83
2.15 Proposed synthesis of phosphorodiamidate (116). 84
2.16 Proposed route to the generalised phosophorodiamidate (133). 86
List of Tables
1 Summary of inhibition data. 62
VI
Abbreviation Meaning
AIDS
AZT
Boc
CA
Chex
Cbz
ddl
diast
DMF
DMSO
DNA
DTT
EDTA
ELISA
EPNP
eq.
FAB
gP
HIV
HMPA
HPLC
IBu
acquired immune deficiency 
syndrome
3^-azido-3^-deoxythymidine
tertiarybutoxy carbonyl
capsid protein
cyclohexyl
carbobenzyloxy
7!, 3'-dideoxyinosine
diastereomer
dimethylform am ide
dimethylsulfoxide
deoxyribonucleic acid
D,L dithiothreitol
ethylene diaminetetraacetic acid
enzyme-linked imm unosorbent
assay
1, 2-epoxy-3-(4-nitrophenoxy)-
propane
equivalents
fast atom bombardment 
glycoprotein
human immunodeficiency virus
hexam ethylphosphoram ide
high performance liquid
chromatography
iso-butyl
Vll
■I
ICso
IN
Ki
MA
MHC
mRNA
N.D.
NMM
NMR
N oa
PR
Qua
RF
RN
RNA
RT
SIV
THF
Thfg
TLC
UV
concentration required to reduce 
enzyme activity by 50% 
integrase
enzyme inhibition constant 
Michaelis-Menten constant 
matrix protein
major histocompatibility complex
messenger ribonucleic acid
not determined
N -m ethylm orpholine
nuclear magnetic resonance
naphthyloxyacetyl
proteinase
quinoline-2-carbonyl
replicative form
ribonuclease
ribonucleic acid
reverse transcriptase
simian immunodeficiency virus
tetrahydrofuran
tetrahydrofuranylglycine
thin layer chromatography
ultraviolet
Vlll
Amino acid Three letter code One letter code
Glycine Gly G
A lanine Ala A
Valine Val V
Leucine Leu L
Isoleucine He I
Phenylalanine Phe F
Tyrosine Tyr Y
Tryptophan Trp W
Serine Ser S
T hreonine Thr T
Cysteine Cys C
M ethionine Met M
Asparagine Asn N
G lutam ine Gin Q
Aspartic acid Asp D
Glutamic acid Glu E
Lysine Lys K
Arginine Arg R
Histidine His H
Proline Pro P
N orleucine Nle -
Cyclohexylalanine Cha -
IX
CHAPTER ONE
i3
INTRODUCTION TO HIV-1
Chapter 1: Introduction
1.0 Introduction.
1.1 General Introduction - The Scale of the Problem
At the end of 1988, around 7 million people world-wide were HIV positive. 
Four years later, this figure had almost trebled to 19.5 million, including almost 3 
million cases of full-blown AIDS, most of whom are already dead.^ Early 
predictions have proved inadequate and the number of people anticipated to be 
HIV positive by the end of the decade ranges from 40 to 110 million people;^ this 
latter figure represents 2 % of the current population of the world. In 1990, the 
W orld Health Organisation predicted that the cumulative num ber of cases of 
AIDS w ould reach 6 million; less than a quarter of these are considered 
preventable.^ Whilst it is true that other diseases, for example malaria, kill more 
people, the rapid spread of HIV, together with the lack of satisfactory treatment, 
means that for the foreseeable future, it will continue to be one of the most 
important areas of research world-wide.
1.2 The Life and Times of HIV.
It is widely believed that the etiological agent responsible for AIDS is the 
hum an imm unodeficiency virus (HIV), although some hold this point in 
contention. Originally referred to as HTLV-III or LAV, infection by the virus 
eventually produces profound defects in cell-mediated im m u n i ty O v e r  time, 
there is a severe depletion of the number of CD4+ T-lymphocytes which leads to 
opportunistic infections, neurologic and neoplastic disease and, ultim ately, 
death.
Although AIDS first came to light in 1981, it was two years before the cause 
was identified.^ The first class, known now as HIV-1, was found in the Western 
World and in Central Africa.^ Soon afterwards, another major sub-type, HIV-2, 
was discovered in West Africa.^ The genomes of the two classes are around 40 % 
identical, although interestingly HIV-2 is almost 80 % identical to the simian 
immunodeficiency virus (SIV). This infects certain African monkeys in the wild
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with no pathological consequence.^ However, in Asian macaques held in 
captivity, and thus not exposed in their native habitat, an AIDS-like disease has 
been observed/ HIV-2 has infected a vast population in W estern Africa and 
several cases have been documented in the West® but, as HIV-1 is the pathogen 
of greater consequence, it is with this strain that the following discussion will be 
mostly concerned.
HIV was found to be a lentivirus, a member of the Lentiviridae family of 
retroviruses; members of this family include both HIV sub-types, SIV and also 
equine infectious anaemia virus (EIAV).
The virus consists of an envelope and a core (see Fig. 1.1). The envelope is 
made up of a lipid bilayer and three proteins, the surface glycoprotein g p l20 on 
the outside, a transmembrane gp41 and a matrix protein p i 7 coating the inside. 
(The p notation used here refers simply to a protein, gp means a glycoprotein and 
the num ber following refers to its approximate weight in kilodaltons, as 
determined by electrophoresis).
The core is roughly bullet shaped. It has an outer skin of capsid protein p24, 
inside which are two strands of RNA, each tightly covered by the nucleocapsid 
protein p7. There are three additional enzymes present: the proteinase p l l ,  
reverse transcriptase p 66 and integrase p32, and a further protein p 6 of 
unidentified function.*
The genome of the virus is encoded in RNA which it transcribes into DNA 
w ithin the host cell for incorporation into the host genome. Subsequent 
expression is then performed by the host cell, under the supervision of the viral 
genes.
RT transcription translation
(viral) RNA --------- > DNA -----------------> mRNA --------------> Polyprotein
Cha^:ler 1: Introduction
MA
Lipid
Bllayer
Figure 1,1: Schematic Representation of the Human Immunodeficiency 
Virus. SU = surface protein gpl20, TM  = transmembrane gp41, M A  = matrix 
protein pl7, CA = capsid protein p24, NC = nucleocapsid protein p7, IN  = 
integrase p32, RT = reverse transcriptase & PR = proteinase.
W ithin each class, there exist many strains of HIV, each of which is distinct 
but clearly related to one or other of the classes. These are brought about by 
errors in conversion of viral RNA to DNA (reverse transcription). This process 
is highly prone to error,^ as the viral reverse transcriptase has no proof-reading 
ability. Errors in base incorporation can occur with a frequency of up to one base 
per 1700,^0 and in a genome of about 9200 bases, this means an average of five 
mismatches per cycle of replication. Furthermore, the process has no DNA 
repair action so each error is retained. So within any one individual patient, 
several distinct variants will exist; in one case, 39 strains in two infected patients 
were reported,^ ^  and in another, a variation in the isolated viruses has been 
observed in the same patient at different times. 2^ The pathological consequences 
of such variability go far to explain the seemingly random  tim ing of the
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development of full-blown AIDS in HIV-positive individuals. Obviously, many 
other factors may influence longevity, but evidence exists to suggest that long­
term  survivors are infected by less virulent strains, and also that virulence 
increases with time.^^
With such heterogeneity and mutability inherent in the nature of the virus, 
it is clear that a thorough understanding of the viral life cycle is vital in order 
that therapeutic measures will be effective regardless of the strain or strains 
present.
1.3 The Life Cycle
The life cycle is still not fully understood and several aspects remain elusive. 
However, the major events in the life cycle are summarised below (see Fig. 1.2).
cellular DI^ A unintegrated 
circular DNA
integrated 
pro viral DNA uncoating
CD4 molecule
HIV
u  ^i_,.genomenc
. . reverse transcriptase^ umntegrated RNase H 
linear DN
protein 
 ^ ^  synthesis
messenger 
RNA
genomic RNA
gly cosy lationassembly and 
budding
mature HIV virions
Figure 1,2: Diagram of the Viral Life Cycle.
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The external portion of the viral envelope glycoprotein gpl20 recognises and 
binds w ith high affinity to the receptor protein CD4. The T-helper (T4) 
lymphocytes, first to be identified as targets for HIV,^/ 4^ have this surface marker, 
as do other targets such as macrophages and m o n o cy tes .H o w ev er, since these 
were discovered, many other cell types have been shown to be infected, 
including cells in the brain,^^ gastrointestinal tract,^^ kidney,^® liver,^9 lung^o and 
nervous system,2i and some of these do not display CD4. Furthermore, some T- 
cells with high expressions of CD4 have been found to be HIV resistant.22 This 
suggests that a second receptor is required for viral entry into the cell.
The transm em brane gp41 penetrates the cell mem brane and initiates a 
process of membrane fusion. This causes the viral core to be expelled into the 
cell.
The nucleocapsid protein needs to be altered so that the RNA w ithin is 
accessible to the reverse transcriptase. This could be carried out by cellular 
proteinases, but there exists in vitro evidence to suggest that the viral proteinase 
is responsible.23
The reverse transcriptase enzyme polymerises deoxynucleotides on the RNA 
template giving single strand DNA. A complementary strand is also synthesised 
and the now double-stranded DNA is transported to the cell nucleus. The 
integrase enzyme is also transported there, where it inserts the viral DNA into 
the host genome to form integrated viral DNA. This process is irreversible and 
thus the presence of the HIV genome in the cell is permanent. This integrated 
retroviral DNA piece is called the p r o v ir u s .2 4
The cell may harbour the provirus for a long time and it is not understood 
w hat activates it. When it is activated, however, it begins to produce RNA 
molecules corresponding to the total length of the viral genome using cellular 
polymerases. Some of these will serve as genetic material for a new generation 
of viruses while the rest, the messenger RNA, migrates to the ribosomes in the
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cytoplasm where synthesis of the polyproteins takes place using the mRNA as a 
template.
Open reading frames (ORF) are regions of the DNA where a substantial 
sequence of amino acids are coded between stop codons.^^a When genes overlap 
in the genome, it means that they are encoded in different reading frames. Each 
amino acid is coded by three codons so the reading frames can be either one or 
two nucleotides out of phase.
W hen the proviral DNA is inspected, several ORFs are revealed. The 
proteins found in the intact virus are derived from three of these: gag, pol and 
env (see Fig. 1.3). Other ORFs encode proteins involved with controlling the 
expression of the provirus and are not packaged in the viral particle. The 
presence of these added genes make HIV one of the most complex of all known 
retroviruses.
Frame-shift
region
Envelope proteins 
allow CD4 binding 
& membrane fusion
nucleocapsid- 
core proteins
.....
Promotes viral 
infectivity
p« pol
!
vif
Promotes efficient 
viral budding
Unknown functioninef
p l5 g ? g R I :R N jg e 2 ^
vpu
5 'LTR
Î Î
env 
14— r : ----------- ►
Binding segments 
for host transcription 
factors
protease(PR) 
reverse transcriptase- 
ribonuclease H (RT-RNase), 
and integrase (IN)
vpr
Vea
tat
rev 3  LTR
k and potent 
activator of all viral 
proteins.
Regulates expression 
of structual proteins
Figure 1.3: The HIV-1 genome.
The gag ORF (1536 nucleotides) is translated into a 55 kDa polyprotein 
including all the structural proteins.24 The pol ORF (3045 nucleotides) is only 
translated as a gag-pol fusion protein.24 it bypasses the gag stop codon due to a
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frame-shift slightly before the stop codon. By moving one base backwards 
(towards the 5' end of the mRNA) the translation can continue smoothly until 
the pol stop codon is reached. This frame-shift is uncommon and results in a gag 
to gag-pol ratio of about 10:1. The pol region encodes the proteinase, reverse 
transcriptase and integrase, i.e. the viral enzymes. Since enzymes are catalytic, a 
stoichiometric amount is not required and using this frame-shift is a subtle and 
efficient way to generate them.
The env ORF is also translated, as a 160 kDa polyprotein.24 This encompasses 
the surface protein gpl20 and the transmembrane protein gp41.
Cellular enzymes carry out post-translational m odification. The env  
polyprotein is glycosylated and cleaved into its two component proteins. 
Myristoylation of the N-terminus of the gag and gag-pol polyproteins also takes 
place. This is a non-polar fatty acid which is used to attach the polyproteins to 
the inside of the cell membrane.
Once the poly-proteins and some genomic RNA have associated near the cell 
membrane, the area 'buds' and a small portion of membrane pinches off to form 
a densely packed sphere about 0.1 microns in diameter.
This non-infectious imm ature viral particle then undergoes a series of 
processing steps catalysed by the viral proteinase. The proteinase catalyses its 
own release and, once free, catalyses a series of further hydrolytic cleavages. The 
matrix protein remains attached to the envelope while the rest of the released 
proteins assemble in the core, along with the two RNA molecules. It is possible 
to watch this m aturation process through an electron microscope as the
doughnut-like centre of the immature particle transforms to the bullet-shaped
1core of the mature v ir u s .2 4 a  1
jA single cell can produce several hundred new viruses, usually killing the |
cell in the process.24a |
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1.4 Therapeutic Targets
Examining the viral life cycle has revealed a number of possible stages for '
in tervention.25
1.4.1 Reverse Transcriptase
Early work on anti-HIV agents was centred on the reverse transcriptase 
enzyme. The process of converting viral RNA to DNA is unique to retroviruses, ^
so an inhibitor of this enzyme should not interfere in the body's other processes. i
This research resulted in the development of the first AIDS therapeutic agent. 
Zidovudine or 3’-azido-2’,3’-dideoxythymidine (AZT) (1). ]
Na
(1): Zidovudine (AZT).
AZT was originally discovered to be an anti-tumour agent^^ and was later 
found to be active against the Friend leukaemia virus.27 In 1985, cytopathogenic 
effect on HIV was found in vitro'^^ and it was subsequently given to AIDS 
p a t ie n ts .29 Other nucleotides also w ent to clinical trials, such as 2',3'- 
d ideoxyadenosine  (ddA ) (2), 2 ',3 '-dideoxyinosine (ddl) (3) and 2',3'- 
dideoxycytidine (ddC) (4). These latter two have both been approved by the US 
Food and Drug Administration (FDA).
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NH
HO
(2): ddA,
NH
HO
(3): ddl
NH
HO
(4): ddC.
However, AZT has shown significant toxicity; indeed some patients cannot 
tolerate AZT therapy at all. With long term AZT treatment, its benefits begin to 
wane. Some m utant resistance has already been observed which does not bode 
well for either ddl or ddC.^o
Some non-nucleotides have also shown activity against reverse transcriptase. 
In particular some benzodiazepines and dipyrodiazepinones have shown potent 
in vitro activity as well as low cytotoxicity and may be clinically useful.^^ The 
tetrahydroimidazo-[4, 5, 1-jk] [1, 4]-benzo-diazepin-2(lH)-one and thione (TIBO) 
derivatives were identified from an evaluation of over 600 classes of 
c o m p o u n d s . 3 2  r-82150 (5) is one such TIBO derivative and is as potent as AZT 
and has a therapeutic index that is five times higher.
(5): R-82150,
Am ongst the l-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) 
derivatives^^ was one derivative (6) which showed an in vitro therapeutic index 
of over 100,000.34
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CH2CH3 QH
H3C °
(6): HEPT derivative.
Nevirapine (7) has also been shown to target reverse transcriptase^^ and it has 
been shown to have activity against an AZT-resistant strain.^^ However, in vitro 
HIV-1 resistance to TIBO derivatives and nevirapine has been reported^^ and it 
remains to be seen whether this will also manifest itself in vivo. However, both 
TIBO and HEPT derivatives show no activity against HIV-2 .^2,33a This may mean 
that the inhibitors cannot compensate for mutations in later generations of the 
virus and that it will be only a matter of time before resistant strains will 
develop.
CH.
(7): Nevirapine.
In addition, some findings point to their association with the development of 
resistant strains of HIV. All this has somewhat dampened enthusiasm for this 
series of compounds.
1.4.2 Proteinase
See sections 1.5 and 1.6 for a fuller discussion.
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1.4.3 Glucosidase Inhibitors
A critical step in the life cycle is the N-glucosylation of the envelope protein 
followed by processing of the product by a number of enzymes. This latter part 
involves a-glucosidases 1 and 11 which remove one or two glucose units from 
the oligosaccharide chain. Inhibitors of these enzymes such as glucose mimics 
castanospermine (8) and N-butyl deoxynojirimycin (N-butyl DNJ) (9) interfere 
with this process and N-butyl DNJ is undergoing clinical e v a l u a t i o n . ^ s
OH OH
h o . , „ X , , . . o h  h o .,„ a
N ^C H gO H
V _ _ /  C 4H9
(8): Castanospermine. (9): N-butyl DNf.
However, there are problems with these compounds: they require high doses 
and also they are non-specific in their recognition of viral and cellular 
glucosylation.
1.4.4 Inhibitors of Gene Expression
A major question in the fight against AIDS is whether it is actually possible to 
cure the disease. This is an issue because of the irreversible nature of the 
integration of the pro viral DNA into the host cell DNA, guaranteeing life-long 
infection. A cure is therefore only possible if an agent can remove the viral 
genome from the host cells. This has not yet been achieved, however, there has 
been some success in blocking expression of viral genes. While this does not 
remove the infection, it may delay or even prevent the onset of full-blown AIDS.
In 1978, the first in vitro experiment was carried out that demonstrated the 
feasibility of anti-sense nucleotides.^^ These are nucleotide analogues which are 
designed to complement a specific segment of genome. This is then hybridised 
with the target sequence which effectively blocks expression. Problems with
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rapid in vivo metabolism by cellular exonucleases were avoided by replacing the 
phosphate linkage with methyl phosphonates (10), phosphorothioates (11 ) or 
phosphonamidates (12) (see Fig. 1.4).40
HO.
V
X o —ÿ
OH
(10) X = CH3
(11) X = S”
(12) X = NHRorNRRi 
B = A, T, C, G
Figure 1.4; Anti-sense oligonucleotides.
To improve cell uptake properties, the oligonucleotides have been linked to 
poly-L-lysine and also to cholesterol. Agents targeting the rev gene have been 
prepared.
There are some other points to consider, such as the susceptibility of these 
compounds to endonucleases and also whether hybridisation will occur in vivo. 
It remains to be seen whether these problems can be overcome.
1.4.5 Viral Binding Inhibition
The high affinity interaction between the surface glycoprotein gpl20 and the 
CD4 receptor is vital for infection to occur. Soluble CD4 derivatives, which 
compete with the T-cells for the gpl20, have been prepared and show anti-viral 
activity in vitro.^'^
While these results were encouraging, in vivo tests showed much poorer 
activity. A further problem with this approach is that HIV is unable to infect
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some cells which display CD4 receptors and is able to infect some CD4 negative 
cells, so this approach cannot be widely applicable.
1.4.6 Tat Regulatory Protein
Some of the benzodiazepines used as non-nucleotide reverse transcriptase 
inhibitors were found to block the viral protein synthesis which is enhanced by 
the tat protein.42 The exact nature of the activity is unclear, but phase I clinical 
trials on Ro-24-7429 have been successfully completed.
1.4.7 Other Targets
Other areas have the potential for anti-HIV action, although work in these 
areas is very much in its initial stages. The regulatory genes tat and rev are 
possible sites for drug intervention. The p l5  ribonuclease H domain of reverse 
transcriptase is another area and with the availability of its X-ray crystal 
structure,43 the impetus to design inhibitors should be provided.
Finally, there is the retroviral integrase enzyme, inhibition of which should 
block incorporation of viral DNA into the host cell DNA. Also, there may be 
other areas which can be exploited as greater understanding of the virus emerges.
1.5 HIV-1 Proteinase ,
It has been known for over twenty years that viruses express their genomic 
products as large polyproteins.44 It was also postulated that they might encode a 
proteolytic enzyme to regulate conversion of these polyproteins to the various 
structural and functional proteins. Such an enzyme would eliminate a reliance 
on cellular proteinases for this process and thus increase its ability to infect and 
replicate in numerous cell types.
Since that was proposed, it has been found that a wide range of viruses do 
indeed encode their own proteinase, including HIV. The first observation of a 
proteinase in a retrovirus was in Rous sarcoma virus, an avian retrovirus.45
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With the beginnings of the AIDS pandemic, researchers looking for potential 
therapies predicted the presence of a viral proteinase and that an inhibitor of this 
m ight provide anti-viral activity with minimal disruption to normal cellular 
processes.
1.5.1 Classification
There are four broad classes of proteinase: aspartic, cysteine, serine and 
métallo proteinases. The HIV proteinase was found to be of the aspartic class, so 
named because of the presence of a pair of highly conserved aspartyl residues in 
the active site of the enzyme. Other, non-viral, aspartic proteinases, such as 
pepsin and renin, have been extensively studied with obvious benefit to the 
initial study of HIV proteinase. The enzyme was so classified on the basis of 
several pieces of evidence:
(1) Examination of the sequence homology of the HIV proteinase enabled the 
identification of a DTG triad observed in the catalytic site of other proteinases 
belonging to the aspartic f a m i l y
(2) The enzyme was inhibited by the prototypical aspartic proteinase inhibitor, 
peps ta tin (13)^7 and also irreversibly inactivated by l,2-epoxy-3-(4-nitrophenoxy)- 
propane (EPNP) (14)48 which had previously been shown to inhibit pepsin by 
estérification of one or. both of the active site aspartate r e s i d u e s .4 9
(13): Pepstatin A.
•   ' /-'■
"1
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(14): EPNP.
(3) Site-directed mutagenesis of Asp-25 to Asn completely abolished activity, 
indicating still further that the enzyme was an aspartic proteinase.^^
(4) Conclusive evidence was provided when the X-ray crystal structure of the 
proteinase was solved.^^ From this, it was found that it was bilobal and was 
comprised of two identical 99 amino acid monomers (mass 11.5 kDa each) with 
each sub-unit contributing one conserved DTG triad to the active site, as had 
been predicted by Pearl and T a y l o r . Though structurally similar to bilobal 
m am m alian aspartic proteinases, the retroviruses have evolved a unique 
m ethod for synthesising a protein not unlike the mammalian equivalent but 
carrying only half of the genetic i n f o r m a t i o n . ^ ^
1.5.2 Preparation and Purification
In order to study an enzyme, a ready supply of that enzyme must be available. 
HIV-1 proteinase has been purified by a number of methods:
(1) It has been isolated directly from the virus i ts e l f .H o w e v e r ,  aside from 
the danger of using this method, it gave a very poor yield of the enzyme and that 
obtained showed very poor activity.
(2) More user-friendly methods utilise standard biochemical techniques of 
cloning and expressing the enzyme in bacteria and yeast. These have been 
reviewed.^'^^'
(3) The small size of the enzyme means it is also amenable to a chemical 
synthesis and this has been effected by a number of researchers using solid state 
resin techniques.
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HIV-2 proteinase has received less attention than its counterpart, but this has 
also been expressed in bacteria and yeast and has been chemically s y n t h e s i s e d . ^ ^
1.5,3 Substrate Specificity
Understanding the enzyme’s preferences for particular residues in particular 
sub-sites is obviously desirable, as it gives a clearer picture of the binding sites 
available which can then be exploited in the design of inhibitors. However, such 
a task is not so straightforward, especially with an enzyme which recognises a 
variety of substrates. Inferences have been drawn from the results of enzymatic 
hydrolysis of peptides based on the natural substrates. The different cleavages 
have been classified into three general types based on the pattern of amino acid 
residues spanning P4 to P4 ' (the Pr/ Pn' terminology of Schechter and Berger^s has
been adopted and prescribes that amino acid residues are num bered P | P2 ....
from the scissile bond to the amino terminus and P |' P2 ' ....  from the scissile
bond towards the carboxy terminus) and attempts have also been m ade to 
explain them in terms of the distribution of hydrophilic and hydrophobic side 
chains.
The sequences of the natural substrates seem to suggest an enzyme that is 
quite specific; however that is not the case. The proteinase has been shown to 
cleave a variety of peptides and non-viral p r o t e i n s . ^ ^ b  Although it has a pH 
optimum of around 5 or 6, it can, depending on the substrate, process peptides at 
up to pH 7 or at low pH.
A minimum of seven residues is required for cleavage to occur, spanning 
either P3 to P4 ' or P4 to Pg’.^  ^ Although smaller peptides are not processed, a 
num ber of potent inhibitors have been made which contain fewer than seven 
residues (see section 1.6). This is in agreement with crystallographic studies 
which suggested the existence of multiple hydrogen bonds to the backbone of 
inhibitors spanning these sites (see Section 1.5.4). The natural substrates are 
shown in Figs. 1.5 and 1.6.
J
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pol env
10 11
p17 p24 P7 p6
MA CA NC NC
PR RT il RN IN
5 6 78 9
gp120 gp41
Prl60&«&-M
where MA = matrix protein 
CA = capsid protein 
p7 NC = nucleocapsid protein 
p6 NC = nucleocapsid protein
PR= proteinase 
RT = reverse transcriptase 
IN = integrase 
RN = ribonuclease
Figure 1,5: The gag, pol and env polyproteins; 1-11 represent 
the sites of cleavage (see Fig. 1.6).
The cleavage sites (*) of the HIV-1 proteinase within the Prl60&^ &-^ (^^  ^are as 
follows:
(P4)-(Pi) (Pi 'HP4')
1. Ser-Gln-Asn-T yr * Pro-Ile-Val-Gln-
2. Ala-Arg-Val-Leu * Ala-Glu-Ala-Met-
3. Ala-Thr-Ile-Met ♦ Met-Gln-Arg-Gly-
4. Pro-Gly-Asn-Phe * Leu-Gln-Ser-Arg-
5. Ser-Phe-Asn-Phe * Pro-Gln-Ile-Thr-
6. Thr-Leu-Asn-Phe * Pro-Ile-Ser-Pro-
7. Leu-Glu-Lys-Glu * Pro-Ile-Val-Gly-
8 . Ala-Glu-Thr-Phe * Tyr-Val-Asp-Gly-
9. Arg-Lys-Ile-Leu * Phe-Leu-Asp-Gly-
Figure 1.6: Cleavage Sites in HIV-1 Proteinase.
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The substrates are often divided into three classes. The first is in general 
Ser/Thr.Xaa.Yaa.Phe/Tyr * Pro.Zaa (where * represents the scissile bond and Xaa, 
Yaa and Zaa represent any amino acid). This sequence has been observed in a 
number of retroviruses but is unknown in other systems. Class two has Arg at P4 
and Phe-Leu in P%'-P2'. The final class has either Gin or Glu at P2 ' .
HIV-1 proteinase will cleave HIV-2 substrates (or vice versa), albeit at a 
reduced rate.^^ A more detailed series of studies looked at Pg/^ P2, Pi^^ and 
From this work, it was concluded that a branched residue, such as He, is preferred 
at P2', although Ala and Leu are also tolerated. The presence of Phe and Gly at 
P2' gives poor substrates while Trp gave rise to a peptide that was not cleaved. He 
or Val at P%, on the other hand, resulted in no cleavage whereas Leu, norleucine, 
Met, Phe or Tyr all make excellent substrates. P3 showed very little selectivity, 
only substitution by Pro gave an inactive peptide. P2 also preferred branched 
residues, but also tolerated Leu, Phe, Ala, Asp or Asn. Gly and Pro were 
unfavourable. In another study, it was found that replacing the Pro at Pi ' with 
pipecolinic acid (the homoanalogue of Pro) gave an inhibitor, rather than a
substrate .^ 4
The subtle interactions of the substrate with the enzyme are still not well 
understood. Indeed, sub-site specificities for different cleavage sites are often not 
in parallel w ith each other.^s Despite this, the information is useful to the 
medicinal chemist as it gives some clues about the sort of functionality to 
incorporate into inhibitors. This also shows that the enzyme is able to tolerate 
residues other than the natural ones thus allowing greater flexibility in inhibitor 
design. This is demonstrated in the specificity studies of the proteinase in 
recombinant proteins. Random mutagenesis of the P i-P i’ positions produced a 
variable susceptibility to cleavage.^^ Although in some junctions (for example 
the PR-RT or RT-IN junctions), little or no change was tolerated, in the p 6-PR 
junction a variety of changes were accepted. Replacing the natural Phe-Pro
%
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cleavage sequence with residues such as Ala-Ile or even Gly-His resulted in 
substrates that were processed at an equivalent rate to the natural substrate.
1.5.4 Structural Properties of HIV-1 Proteinase
Non-viral proteinases are monomeric, contain more than 300 amino acids 
and are 'pseudosymmetric' in that they are bi-lobal.^^ One catalytic aspartate is 
contributed by each lobe and these are situated at the bottom of the cleft formed 
by these lobes.
The retroviral proteinases on the other hand have fewer than 130 amino 
acids and have minimal sequence homology with their non-viral counterparts, 
w ith only two domains conserved. The first of these, Leu-Leu(Val)-Asp- 
Thr(Ser)-Gly-Ala contains the catalytic triad and is identical to the domain found 
in the non-viral proteinases. The second domain is Ile(Leu)-Leu-Gly-Arg-Asp. 
The structure and function of retroviral proteinases has been recently 
reviewed.^®
Pearl and Taylor proposed that the retroviral proteinases achieve structures 
equivalent to their non-viral counterparts by d i m e r i s i n g . 5 2  This results in an 
overall similarity to the bilobal structure. The HIV-1 proteinase is roughly 
ellipsoid, measuring approximately 55 x 35 x 25 Â (see Fig. 1.7).
When unbound, it is C2 symmetric, a symmetry which is perturbed upon 
binding of an unsymmetrical substrate.^^ It is very similar to the equivalent 
proteinase from the Rous sarcoma virus (RSV) as well as archetypal fungal 
p ro te in a s e s .70 This is particularly striking when the two active sites are 
superim posed; indeed the features of the HIV-1 proteinase were correctly 
predicted by modelling studies based upon the crystal structure of RSV 
proteinase.7i The enzyme has a P-sheet structure, typical of aspartic proteinases, 
in which the two catalytic triads are in a loop which forms a number of hydrogen 
bonds to the opposite loop, giving the ’fireman’s grip' that is a feature of the 
active site of aspartic proteinases (see Fig. 1 .8 ) .7 2
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Asp-215 
H O CO CHg Thr-216
GHoGOoH } X/
GHaGOa f^JjH 
Asp-32
Thr-33 H Q
Figure 1.8: The 'Fireman's Grip', the Interaction of the Two 
Catalytic Triads, Shown in Pepsin.
The termini of each monomer interact strongly with each other and this 
interaction is thought to be important in maintaining the stability of the dimer. 
They are arranged in a netw ork of anti-parallel |3-sheets, form ing four 
interdigitated strands. It is in this region of the viral poly-protein where the 
initial cleavage takes place, freeing the proteinase in an autoproteolytic event. 
However, this region of the enzyme is somewhat remote from the active site, so 
it is probable that the mechanism for cleavage is intermolecular. The stability 
conferred on the enzyme by this interaction also allows an alternative strategy to 
be envisaged that might deactivate the enzyme.5^<=' 73 jf enzyme cannot form 
the dimer, it is unable to function. Evidence for the potential success of this 
strategy comes from an experiment which complexed a m ixture of HIV-1 and 
HIV-2 proteinases.74 The resulting dimer was found to be inactive. However, no 
further advances on this have appeared so far.
Another feature of the proteinase is the presence of two identical 'flap' 
regions, analogous to the single flap of the non-viral proteinases.
Loeb and co-workers made non-conservative replacements for each residue 
in the proteinase and found some regions to be critical.75 Upon replacement of a 
residue with a residue of different polarity, the proteinase was found to be
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inactive. The regions found were 22-33 (the catalytic domain), 47-52 (the flap 
region) and 77-87.
Enzyme-inhibitor complexes can give a medicinal chemist a good deal of 
information about how inhibitors interact with the enzyme and thus some clues 
as how to go about improving these interactions. A number of such complexes 
have been studied with a variety of structurally diverse in h i b i t o r s .^ ^ ,  76 These 
have revealed a num ber of common factors in enzyme-inhibitor complexes. 
First, despite the range of inhibitors that have been complexed, the overall 
proteinase structure is similar in all cases. Only a slight reorganisation of the 
core is observed, although the flaps can move by as much as 7 A upon binding.69 
In this contracted conformation, the flaps form the top half of a protected 
hydrophobic tube extending roughly from P3 to P3’. The effect of this is to shield 
about 80 % of an inhibitor from the surrounding solvent.
Secondly, structural studies have also revealed the presence of two active site 
water molecules in the inhibitor-enzyme complexes. One is hydrogen-bonded to 
the amide NHs of Ile-50 and Ile-50' (in the flap region) in a tetrahedral fashion 
which seems to act as a latch to keep the flaps closed. The other lies between P% - 
P2 and Pi'-Pz' carbonyl oxygens in the inhibitor and seems to assist in ensuring a 
p-sheet-like conformation for the inhibitor.
All the inhibitors are bound in an extended conformation spanning P4 to P3 ' 
with a netw ork of hydrogen bonds mostly from the backbone of the 'floor' 
(which is the bottom of the cleft formed by the flaps closing) and from the flap 
region. The studies showed no apparent interactions between the active site 
asparta tes and the amine function of either the reduced  am ide or 
hydroxyethylamine inhibitors (see section 1.6 for examples of these types of 
inhibitor), with the binding pockets for P% through to P2 ' alm ost entirely 
hydrophobic in nature.69,76b
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1.5.5 Catalytic Mechanism
An understanding of the mechanism by which an enzyme acts is crucial in 
order to design an inhibitor to counter i t  For this reason, num erous kinetic 
studies have been undertaken in order to elucidate this mechanism.77 Results 
include the inhibition of the enzyme by pepstatin (Ki < 2 pM),78 a pH optimum 
of 4.5 to 6.Q77 and a time dependent inactivation by E P N P . 7 7 b  Furthermore, the 
pH dependence of the kinetic constant log (kcat/Km) for several oligopeptide 
substrates constituted a bell-shaped curve of a pH range of 3.4 to 6.5. This 
indicated that there was an unprotonated group w ith a pKa of 3.4 and a 
protonated group with a pKa of about 6.5 that were required for catalysis.77f This, 
together with the identification of the proteinase as being of the aspartic family, 
indicated that Asp-25 and Asp-25' were involved and that one was protonated 
and the other was not. Substrate cleavage experiments done in H2^®0 resulted in 
the incorporation of into the product and, by way of the reverse reaction, into 
reform ed substrate.77e This indicated the presence of a nucleophilic water i
molecule, especially since there was no incorporation into the enzyme.
These results showed the chemical mechanism to be of the general acid- 
general base type (see Fig. 1.9). This only shows the general features and there is 
some debate over the precise details, such as the protonation state of the 
tetrahedral intermediate, the timing of proton switches and the orientation of 
the scissile carbonyl with respect to the catalytic aspartates. The proposals of 
D a v i e s , 79 Blundell,®^ Pearl,®^ P o l g a r ^ z  and James^^ give a more thorough 
treatment of the mechanistic problem.
However, the above mechanisms all contain a tetrahedral interm ediate 
generated by a nucleophilic water molecule (catalysed by the aspartates) so in 
accordance with theories regarding the enzymatic stabilisation of the transition 
state, the amide hydrate intermediate would be expected to be very tightly bound 
by the e n z y m e . 8 4  Therefore, an inhibitor which mimics this transition state 
would be expected to be similarly tightly bound. The concept of transition state
3
" ' f..-■ ■ ."o..., A,, ......
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mimicry has been used by the great majority of research groups synthesising and 
testing inhibitors for HIV-1 proteinase.
Asp 25
Asp 25’
Asp 25
Asp 25’
Asp 25 Asp 25'
Figure 1,9: The Mechanism of General Acid-General Base Catalysis.
1.6 Proteinase Inhibitors
Since Kramer proposed that the viral proteinase was a viable target for anti­
viral agents/^ a great deal of effort has been directed towards the design and 
synthesis of proteinase inhibitors. The classical strategy makes use of the concept
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of a transition state mimic, in which the transition state is replaced by a non- 
hydrolysabie moiety. Although this could be any functionality, one which has 
similar structural and electronic features is obviously a more realistic mimic.
This strategy worked well for renin,^^ ^ mammalian aspartic proteinase, and 
that work has served as something of a blue-print for HIV proteinase inhibitors.
There are a wide range of isosteres utilised; some of the more common ones 
are shown below:
HN. ,CH HN.‘N'Ha
OH,
R
,OH ,CH
'■F
HN.
OH
,CH
Reduced amide
HN.
OH
Ha
Hydrated difluoroketone 
OH
HN. ,H HN.
Ha
Staline
0
1 ,CH
R Ha
-OH IOH HaR
HN
Hydroxyethylene
OH
i^H .NH HN
R O
Norstatine
Hydroxyethyi amine 
OH
^  ^OHT r:
Phosphinate
OH
HN. .H I-N NH
X TR O
HydroxyethylureaDihydroxyethylene
Figure 1,10: Transition State Mimics,
A study by Dreyer and c o - w o r k e r s ® 7  compared five of these isosteres by 
incorporating them into the same (or at least highly similar) peptide backbone 
(see Fig. 1.11). This study showed the hydroxyethylene moiety to be most potent, 
followed by difluoroketones, then statines and phosphinates and reduced amides 
as the least potent. While the peptide backbone was not precisely the same for 
each mimic, it does convey a good impression of the relative efficacy of each 
moiety and other comparisons have shown similar trends.^®
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O( 1 5 )
Ki = 19000 nM.
Ser-Ala-Ala
^ O OH O
Val-Val-OMe
( 1 6 )
Ser-Ala-Ala. Val-Val-OMe
Ki = 8 1 0  nM.
OH O
( 1 7 )
Boc-Ser-Ala-Aisu
Ser-Ala-Ala^
Val-Val-OMe K, =160nM.
Ki = 62  nM.
Val-Val-OMe
( 1 9 )
Figure 1.11: Comparison of Transition State Mimics.
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1.6.1 Reduced Amides
This class of inhibitors proposes a methylene group (CH2) as a transition state 
mimic of C(OH>2. There are obviously severe drawbacks with this proposal; it 
doesn 't possess the hydrogen-bonding capability and is not very similar 
structurally. That said, it can be an effective inhibitor and its potency against 
renin was thought to be due to the amine being protonated to give an 
electrostatic interaction with the anionic aspartates. According to Hyland and co- 
workers,®^ there is a requirement that both aspartates be unprotonated, which is 
not the case for HIV proteinase and this may go some way to explaining the 
reduced amide's lower potency against this enzyme.
However, that is not to say that no effective inhibitors have been made. A 
synthetic substrate derived from the pl-p7 cleavage in Pr55^% one of the best for 
HIV-1 proteinase, was converted into its reduced amide (20) and this became an 
inhibitor with a K\ of 780 nM.^^
H
O
Gln-Arg-NH2
(20): Norleucine-based inhibitor (K^  = 780 nM).
Urban and co-workers improved this f u r t h e r ; ^ !  compound (21) had a Ki of 
23 nM while compound (22) was the most potent with a K| of only 0.2 nM.
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OMe
(21): A potent reduced amide inhibitor (Kj = 23 nM).
OMe
(22): A highly potent reduced amide (Kj = 0.2 nM).
1.6.2 Phosphinic Acids
The phosphinic acid class has been very successful in the past and phosphinic 
acid inhibitors of pepsin were amongst the most potent r e p o r t e d . ^ 2  However, 
initial attempts to get similar results with HlV-1 proteinase were disappointing. 
This is possibly due to the anionic nature of the phosphinate at the assay pH of 
6.0. The pKa of a phosphinic acid is in the region of 3 to 3.5, so it would be 
predom inantly ionised and there is precedent for the repulsion of negatively- 
charged species away from a negative aspartate.^^ With the lower pH optimum 
of pepsin, more protonated phosphinate was present which led to greater 
inhibition. This theory is backed up by an experiment with the HlV-1 proteinase; 
lowering the assay pH from 6.5 to 4.5 gave a 500-fold increase in p o t e n c y
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A potent phosphinic acid has been reported by Abdel-M eguid and co- 
workers.^5 SB 204144 (23) had a Ki of 2.8 nM at pH 6. Their pH analysis failed to 
unambiguously determine the question of whether the inhibitor would be much 
more potent at lower pH, however, crystallographic results indicated the 
presence of a protonated phosphinate.
O
H II H Cbz— VahN^ VahCbz
Ph*^  Ph
(23): SB 204144, a potent symmetrical phosphinic acid inhibitor (Ki =2.5 nM).
1.6,3 Statines
The archetypal aspartic proteinase inhibitor is Pepstatin A (13) and this was 
used as part of HIV-1 proteinase's characterisation as belonging to that class. 
Pepstatin A shows a Ki of approximately 1 |iM. A substrate analogue (17) (which 
pepstatin is not) only gave a Ki ' of 0.81 p.M.^7 More rem arkably still, acetyl 
pepstatin gave a Ki of 20 nM,^^ despite only the addition of an extra acetyl group 
at P4.
A related group are the norstatines; these have been shown to be effective 
inhibitors. Com pound (24) showed a Ki of 5 nM^7 whereas com pound (25) 
showed a Ki of 0.58 nM .^ 8 Both show a preference for the (S)-hydroxyl; when this 
is changed to (R), there is a 20-fold drop in potency.
Ser-Phe-AsrrN
OH
(24): Allophenylnorstatine based inhibitor (Ki = 5 nM).
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CONH2
(25): Highly potent norstatine based inhibitor (K  ^= 0.58 nM).
1,6.4 Difluoroketones
This is a highly potent class of inhibitors. Their potency stems from their 
ability to form a stable hydrate species, which is obviously a very close mimic of 
the substrate transition state. Two examples are shown below: compound (26) 
has an IC50 of 1.0 nM^^ and compound (27) has a Ki of 0.1 nM.^^^
Cbz-Gly-Val-NH
(26): Possessing an IC^q value of 1.0 nM. 
Ph,
Cbz-Val— N H
N—Val-Cbz
(27): Symmetry-based difluoroketone (Kj = 0.1 nM).
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1.6.5 Hydroxyethylamines
Another highly potent class. Their efficacy is demonstrated by Ro-31-8959 
(28)^ 0^  which is currently being evaluated in a clinical setting and looks likely to 
be the first HIV proteinase drug on the market. It is highly potent in vitro (Ki = 
0.12 nM) but it also displays in vivo activity in the low nanomolar range against 
HIV-1, HIV-2, SIV and also some AZT resistant s t r a in s .^ ^ z
CONHg
N —‘Bu
(28): Ro 31-8959, a highly potent inhibitor %  = 0.12 nM).
The success of Ro-31-8959 has prom pted a good deal of derivation. Notable 
work comes from Merck's laboratories at West Point including the report of a 
sulfolane (29) (Ki = 3 nM).^03 Also, incorporation of a tetrahydrofuranylglycine in 
place of the Asn in Ro-31-8959 led to the extremely potent inhibitor (30), which 
has an IC50 of 0.054 nM.^04 More recently they have entirely replaced the 
quinoline-2-carbonyl-Asn moiety with a fused 5is-tetrahydrofuran ligand, giving 
a potency equivalent to (28), despite being a lot s h o r t e r .  105
H
OH
N -Bu
(29): Possessing a sulfolane ligand (K  ^= 3 nM).
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(30): Incorporating the (3'R)-Thfg ligand (IC5 0  = 0.054 nM).
OH
H
(31): Incorporating a fused bis-THF ligand (IC5 0  = 1.8 nM).
1.6.6 Hydroxyethylenes
As might be expected after Dreyer's study found it to be the most potent 
isostere, the hydroxyethylene is the most used of all the transition state mimics. 
Popular residues include benzyl in Pi and P i ’ for a phenylalanine analogue, 
although cyclohexylmethyl is occasionally employed with equal effectiveness. At 
P2', the 1 -amino-2-hydroxy-indan is a potent addition as is amino-benzimidazole. 
At P3 ', the amino-methyl-pyridine is a popular choice. These are illustrated 
below: com pound (32) has a Ki of 70 com pound (33) has an IC50 of
0.3 nM^07 and compound (34) is still the most potent HIV-1 inhibitor to date with 
an IC50 of 0.03 This last inhibitor has the unusual styrene at P i’, which
shows that the pocket to be of large size. This last point is emphasised by
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modelling studies that showed that C^o derivatives will fit snugly into the active 
site3^^
(32); Cha-Val hydroxyethylene inhibitor (K  ^= 70 nM).
> r T i
H OH
(33): Highly potent pentapeptide inhibitor (IC^q = 0.3 nM).
BoC'NH N - ^
N
(34): The most potent inhibitor of HIV-1 protease to date.
Another notable hydroxyethylene is CGP53437 (35) which is potent (Ki = 
0.2 nM) bu t more interestingly, displays potent in vivo activity and oral 
bioavailability in mice.^^o
Chapter 1: Introduction 34
BocNH,
Ô ^  "  O
(35): CGP53437r orally hioavailable hydroxyethylene.
1.6.6.1 M odified Hydroxyethylenes
A num ber of subtle changes to the basic hydroxyethylene template are now 
being made in order to alter the properties of the compounds such that they will 
make good drugs. One example is the dihydroxy-ethylene (36) which has a Ki < 
1 nM.^^^ Other compounds of note are the hydroxyethyl-urea of Getman and co- 
workers^i2 and the substituted hydrazine of Sham and co-workers.^^^
OH O
Noa-His-NH
(36): Dihydroxyethylene inhibitor (Ki value < 1 nM).
Another orally active compound is the hydroxy-am ino-pentane-am ide of 
Vacca and co-workers, L-735,524 (37).^^  ^ This had a Ki of 0.34 nM against HIV-1 
proteinase and 3.3 nM against HIV-2 proteinase. It also showed effective anti­
viral activity and displayed oral bioavailability of between 14.2 % in monkeys 
and 71.6 % in dogs and it is now being evaluated in phase I clinical studies.
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*
(37): L-735,524, a potent orally available hydroxy-amino-pentane-amide.
1.6.7 C2-Symmetric Inhibitors
The HIV-1 proteinase is a homodimer; it is symmetric about a C2 axis. 
Therefore, there could be a strategic advantage in designing inhibitors which are 
similarly symmetric, Kempf and co-workers first proposed this,^^^ suggesting 
that there might be an increase in potency as well as an increase in specificity, 
since mammalian aspartic proteinases, though bilobal, are not symmetric. There 
is also a reduction in peptidic character.
They proposed two possible inhibitor cores, as shown in Fig. 1.12.
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Figure 1.12: Design of Ci-symmetric inhibitors.
Strategy A gave A-74704 (38), a potent inhibitor of HIV-1 proteinase in vitro 
(IC50 = 3 nM) and possessing sub-micromolar anti-viral activity.
Cbz—N H Cbz
(38); A-74704, Cz-Symmetric inhibitor (IC^q = 3 nM).
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Using the second strategy gave diols which were generally 10-50 times more 
potent than its equivalent alcohol. For example, the diol equivalent to (38) 
possessed an IC50 of 0.22 nM. Interestingly, both (3R, 4R) and (3R, 4S) diols were 
equi-potent. However, poor solubility meant they were unsuitable as anti-viral 
agents. Studies on these compounds showed that the terminal positions were 
exposed to the solvent. So solubility enhancing efforts were directed at those 
portions of the molecule. This did lead to improved solubility and the potency 
was retained. The most potent of this series was A-77003 (39) and this was put 
into phase I and phase II clinical trials.^^^
CH3
(39): A-77003, Cz-symmetric diol (IC5 Q < 1 nM).
Although some AZT resistant strains of HIV have been observed, it was 
hoped that a similar situation would not occur for the anti-proteinase drugs; 
however, there have been reports of a proteinase strain with increased resistance 
to C2 symmetric inhibitors. One report found substantial decrease in inhibitory 
activity in A-77003 as well as several other diol-based inhibitors, although Ro-31- 
8959 was equally effective against all strains.^^^ The resistant m utant was the 
result of a single amino acid substitution from Arg-8 to Gin or Lys, but it should 
be noted that Arg-8 is highly conserved. Another report isolated five strains that 
were 6 to 8-fold less susceptible to P9941, a compound not dissimilar to A- 
77003.1^ ® Again, Ro-31-8959 was unaffected.
Further, crystallographic studies have shown that the electronic environment 
around  the active site aspartates is assym m etric w hich m ay prom ote 
assymmetric binding, even in inhibitors assuming an exact C2 symmetric
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conformation.^ Dreyer and co-workers confirmed this,!^^ saying that one 
hydroxyl binds between the aspartates (see Fig 1.13) while the other one can only 
make a minor contribution and may contribute negatively.
v/W ' sA/V' s/VV'
> - cR" "R
Asymmetric Binding 
Figure 1.13: Symmetric and Asymmetric Binding in Symmetric Diols.
R ' "R
Symmetric Binding
To test this theory, Kempf and co-workers synthesised A-78791, the 
deshydroxy analogue of A-77003 and found it to have greater potency than the 
diol.i^i This led to the discovery of A-80987, which is a shorter, bioavailable 
analogue of A-78791 and has now been entered into phase I clinical t r i a l s . i 2 2
1.6.7.1 Other 0% Symmetric Inhibitors
Other reported symmetrical inhibitors include the difluoroketones of Sham 
and co-workers (see section 1.6.4) and the phosphinic acid analogue of A-74704 
(see section 1.6.2). Another notable inhibitor is the combined phosphinic acid / 
hydroxyethylene (41) of Stowasser and co-workers, which was designed to 
specifically examine asymmetric binding and gave an IC50 of 0.5 nM.i23
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Nal—Val— N N-V al-Nal
OH OH
(41): Combined Phosphinic acid/ Hydroxyethylene (IC5 0  = 0.5 nM).
Following on from the work of Kempf and co-workers, Barrish and co­
workers proposed a third axis of rotation. Axis C (see Fig. 1.14). This led them to 
synthesise the amino-diol (42) which showed an IC50 of 125 nM.^^^
io ^  ,N .
Ph
P1
/
C2
H HO h HO
N. N
Ph/
Figure 1.14: Axis C.
Ph
y
Boc^H H^BocN
HO HO
(42): Amino-diol inhibitor derived from Axis C ( I C 5 0  = 125 nM).
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NH
(43): Antifungal antibiotic Cerulenin (IC^q = 2.5 mM).
Molecular m odelling studies, in which molecules were docked into the 
enzyme active site and evaluated for complementarity, revealed Haloperidol
(44), which had a Ki of 100 pM.^28
4
i
1.6.8 Non-Peptides
Though peptides can be extremely potent enzyme inhibitors, they rarely make 
good drugs. What is required is a combination of good biological activity and 
good bioavailability; it must not only be an effective agent, it must also be able to 
reach the target cell. Peptides tend not to meet these requirements because they 
are often broken down either by proteolytic enzymes or simply due to instability 
under the biological conditions. They also tend to be rapidly eliminated from 
plasma and have poor trans-membrane transport p r o p e r t i e s . ^ 2 5
There are ways round this; this has met with limited success with renin. A 
reduction in molecular weight, less amide bonds and greater water solubility all 
enhance the pharmacological properties of compounds. Likewise, blocking the 
terminal positions to avoid enzymatic degradation is similarly useful .^ 6^
However, it is often the case that peptides are used to pinpoint the binding 
requirements for an enzyme and what is learnt from these studies is applied to |
the design of non-peptide inhibitors which will hopefully have the correct 
biological properties to make good drugs.
1.6.8.1 Natural Products
One of the first non-peptide inhibitors of HlV-1 proteinase discovered was the 
anti-fungal antibiotic Cerulenin (43), a weak inhibitor with an IC50 of 2.5 mM,i27
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(44): Haloperidol (K^  = 100 pM).
A  num ber of haloperidol-related inhibitors have since been produced, the 
most potent being UCSF 142 (45) which was an irreversible inhibitor with a Kj of 
approximately 10 |iM against both HlV-1 and HlV-2 proteinases.^^^
OH
X r = '01
(45): UCSF 142, Haloperidol-related inhibitor (Ki =10 pM).
Curcumin (46) was also found to be a weak inhibitor of HlV-1 proteinase with 
a potency comparable to Haloperidol.^^o
H3CO OCH,
HO ^  ^  "OH
(46): Curcumin (IC5 0  = 100 pM),
The authors also made a variety of boron complexes; the best one was (4 7 ) 
below, with an IC50 of 6 pM.
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H3CO
H3C0 OCH
HO" ^  ^  "OH
(47): Curcumin Boron Complex (IC5 0  = 6 pM).
A  remarkable result was that the dicarboxylic acid HO2C-(CH2)20-CO2H also 
inhibited the proteinase with an IC50 of 12 Brinkworth and co-workers
proposed this to be due to the dianion and thus synthesised a wide range of 
disulfonates.132 This led to (48) which had an IC50 of 0.78 pM.
NH
N=N
SOqNa
N=N
NH,
(48): Disulfonate (IC5 0  = 0.78 fjM).
Potts and Faulkner isolated didemnaketals which showed activity against the 
enzyme.^3^ Didemnaketal A (49) had an IC50 of 2 pM.
Vi
Chapter 1: Introduction 43
HO COCH
(49): Didemnaketal A
H um ber and co-workers came upon a penicillin derivative. D uring a 
screening program, they found a crude penicillin dimer to be active, but on 
isolation found that the main component to be inactive. The active component 
was eventually found to be a diester derived from the opening of the p-lactam. 
A number of derivatives were prepared to increase the activity leading to (50) 
with an IC50 of 0.9 nM.^^^
NH
Ph. HN
HN
CONHCH
(50): A Penicillin-derived symmetrical dimer (IC^q = 0.9 nM).
Other natural products have been found to be inhibitors of HIV-1 proteinase: 
these include carnosolic acid (51),^^^ cytochalasins such as L-696,474 (52)^36 and 
tetronic acid homologues (53) - (58) (see Fig. 1.15).i37
" '■ -'t-' '
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HO.
HOgC
H3C CH3
(51): Carnosolic acid.
44
ii>*C H<
(52); L-696A74.
1
O Na+ (53): = C % R 2 =H
(54): R  ^ =CH2CH3,R 2 = H
(55): R  ^ =CH3,R 2 =CH3
(56): R  ^ = CH2CH2CH3, R2 = H
(57): R  ^ =CH(CH3)2,R 2 = H
(58): R^  = CH(CH3)(CH2CH3), R2 = H 
Figure 1,15: Tetronic Acid Homologues.
1.6.8.2 Heterocyclic Inhibitors
A num ber of heterocyclic com pounds have been prepared  as HIV-1 
proteinase inhibitors. Amos B. Smith III and co-workers have been developing 
peptidomimetic molecules, in particular |3-sheet mimics, and applied their work 
to HIV proteinase.^^ 8 Their initial target was at least of comparable potency to the 
hydroxyethylene they had based their design on, but only a minor amount of 
optim isation led to (59) which was potent in vitro (IC50 = 1.3 nM) but also 
displayed good transport properties, having a CIC95 of 800 nM (CIC95 is the 
cellular inhibition concentration to reduce enzyme activity by 95 %).
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CTYo—' o
(59); p-Sheet mimic (IC5 0  = 1.3 nM).
A  number of porphyrins have also been prepared, but it was the boronated 
porphyrin (60) that was found to be most potent of the series (IC50 = 185 nM).i39
C2H ^  -j B-| qOCO
C2H11 Bi qOCO
N N
N N
,OCOB-|oH-|-|C2
OCOB-|qH-|-jC2
HOOC COOH
(60): Boronated Porphyrin (IC5 0  ~ 155 nM).
Lam and co-workers synthesised a series of cyclic ureas which were designed 
to displace the structural water molecule that binds the flap isoleucines and thus 
keeps the flaps closed.^"^  ^ The resulting molecules were highly potent and very 
selective, with no inhibition of renin, pepsin or cathepsin D at concentrations 
greater than 3000 times the Ki they showed against HIV-1 proteinase. 
Furthermore, X-ray crystallography showed that the structural water was indeed 
displaced, lending credence to this strategy. (61), containing a cyclopropane side- 
chain, showed a Ki of 2.14 nM and was 100 % bioavailable in rats, although this
■>
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figure was somewhat lower in dogs. DMP 323 (62) was of ten times greater in 
vitro potency (Kj = 0.27 nM) and, although its bioavailability in rats was less, in 
dogs it was of equivalent bioavailability and this compound has been entered 
into phase I clinical trials.
P h ^  L
HO OH
Figure 1.16: Cyclic Ureas.
OH
Flavone and pyranone-type inhibitors have also been a popular target. A 
range of natural and modified flavones have been tested and the best of that 
series was the fully demethylated Gardenin A (63), with an IC50 of 11
OH O
OH
OH
(63): Demethylated Gardenin A.
Many groups took up this lead. Tummino and co-workers have reported 4- 
hydroxy-pyranones such as (64) and (65) which display low m icrom olar 
inhibition but are completely achiral.^^^
O' "O
(64): 4-Hydroxy-benzo-pyran-2~one ( I C 5 0  = 2.7 pM).
Chapter 1: Introduction 47
(65): 4-Hydroxy-6-Phenyl-pyran-2-one (IC5 0  = 3.5 pM).
Lunney and co-workers prepared a range of hydroxy-coumarins which were 
sub-m icrom olar, the best being (6 6 ) shown below which had an IC50 of 
0.52
HO' ^  ' O '  ' O  
(66): 4-Hydroxy-Coumarin (IC5 0  = 0.52 pM).
The best of this series of compounds, however, is U-96988 (67) which, as a 
m ixture of diasterom ers possessed a Ki of 38 nM (32 nM against HIV-2 
p r o t e i n a s e ) . 144 p- was also selective; at 10 |liM i t  didn 't inhibit either renin or 
gastricsin, and only inhibited pepsin and cathepsin D approxim ately 50 %. 
Furthermore it was found to be orally bioavailable in rats and dogs and has now 
entered phase I clinical trials.
(67): U-96988, potent Hydroxy-Pyranone (Ki = 38 nM).
CHAPTER TWO
RESULTS AND DISCUSSION
Chapter 2: Results and Discussion
2.0 Results and Discussion
2.1 Design of HIV-1 Proteinase Inhibitors
The identification of a viral proteinase in HIV revealed a promising new 
target for therapeutic intervention. It has been shown that proteinase activity is 
vital for viral m a t u r a t i o n ^ o  so inhibitors of the enzyme should slow or even stop 
the spread of infection and the onset of AIDS.
The strategy used by the majority of research groups was the same as was used 
so successfully w ith renin,®^ in which a good peptide substrate sequence is 
identified and the scissile bond replaced by a non-hydrolysable moiety.
We were interested in synthesising inhibitors for HIV-1 proteinase, in order 
to both study the enzyme and evaluate a novel series of inhibitors. The 
phosphonamidate isostere was selected for incorporation into a series of HIV-1 
proteinase inhibitors due to close geometric and electronic resemblance to the 
transition state of the substrate (see Fig. 2.1). It has the correct tetrahedral
OPH v„x.
Tetrahedral intermediate
X v "o
X X
Phosphonamidate
Figure 2,1: Comparison of Tetrahedral Intermediate and 
Phosphonamidate Isostere.
geometry as well as providing both oxygens present in the gem-diol. It is worth 
noting that phosphorus-oxygen bonds are approximately 10-15 % longer than 
their corresponding carbon-oxygen ones.^^s This means that the P-O double bond 
can conceivably mimic the lengthening carbonyl as it is attacked by the
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nucleophilic water molecule and the P-O single bond can mimic the approaching 
water.
The phosphonam idate, unlike many other transition state mimics, also 
contains the nitrogen in P% ' which is a potentially important source of hydrogen- 
bond interactions within the enzyme's active site.
A number of problems do exist; at the assay pH, the phosphonamidate will be 
negatively charged (the pKa of a phosphonamidate is approximately 3 to 3.5^46) 
and this will interact unfavourably with a similarly negatively-charged aspartate. 
Also there is a question over the exact nature of the transition state or high 
energy intermediate, as to whether it is a gem-àio\ or a gem-diolate (see Fig. 2.2). 
A simple way to circumvent this problem is to investigate the methyl ester 
(which is an intermediate in the synthesis of the free phosphonamidate anyway) 
and compare their interactions.
N R‘oVH ' 'R  
Substrate
HI H O . .O H
r X  ' x  
/  \
Gem-diol
0.
R
^  /OCH3
^NR'o
R
H ' \  
Gem-diolate
NR’n
H' 'R  
Phosphonamidate methyl ester
H^ R^ 
Phosphonamidate
Figure 2,2: Comparison of Gem-Diol and Gem-Diolate with 
Phosphonamidate Methyl Ester and Phosphonamidate Respectively,
McLeod et al. found that the methyl esters are much more acid stable^^y which 
is immediately advantageous. The P-N bond in the phosphonam idate is acid- 
labile and possesses a short half life in acidic solution. Furthermore, although it
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can accept hydrogen-bonds from the active site aspartate, the phosphonamidate 
has no hydrogen-bond donating ability unlike, for example, a hydroxyethylene. 
The fact that the hydroxyl-containing compounds tend to produce the most 
potent inhibitors suggests that both hydrogen-bond acceptor and donator ability 
is crucial for optimal interaction with the active site aspartates.
Despite this, in terms of charge density distribution, the phosphonam idate 
methyl ester has been shown to be a good mimic of a gem-diol interm ediate. 
There is overall agreement between the relative charges on each atom as 
calculated by semi-empirical quantum m e c h a n i c s ^ (ggg pig. 2.3). Particularly 
notable are the oxygens and nitrogen, for which the phosphonam idate moiety 
was first chosen for investigation. Ab initio calculations have shown similar 
results to those shown above.^^^
-0.628 -0.463 -0.393 -0.422
O. O - C H  
CH
0.243 
.186
H
1.093 -0.559
-0.108
-0.147
N—— CH;
-0.6130.471
0.454
Figure 2.3: Comparison of the Relative Charges on a Phosphonamidate
Methyl Ester and a Gem-Diol.
The design of an initial target was based on the sequence:
Phe-Asn-Phe-Pro-Ile-Val
Each of these residues appears at least twice in their respective positions in 
the natural substrates (see Fig. 1.6). The Phe-Pro amide is the scissile bond in this 
sequence, which was replaced with a phosphonam idate. At the C-terminal
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position was the Val surrogate, zso-butylamine and in P3 was a benzyloxycarbonyl 
(Cbz) group. Camp^^o and Hawkins^^^ had begun this synthesis and Camp had 
found  tha t the Cbz group was unstable under the conditions of 
phosphonamidate methyl ester deprotection, therefore this was substituted with 
a ferf-butyloxycarbonyl (Boc) group. The initial target thus became (68), with the 
intention to also examine the methyl ester (69).
CONH2
Me. .Me O t  H H
°  ' O h
(68) R = Li
(69) R = CH3
This target had been reached by Camp et and the synthesis of a series of 
phosphonam idate-based inhibitors was then undertaken. This included the 
synthesis of small peptide fragments for incorporation on the C-terminal side of 
the inhibitor and also synthesis of phosphoamino acids for incorporation at P i .
2.2. Synthesis and Testing of Phosphonamidate-Based Inhibitors for HIV -1 
Proteinase
Phosphonam idates were first used as inhibitors of the zinc protease 
carboxypeptidase A. Although different in many respects, zinc and aspartic 
proteases do share similar mechanisms. The dipeptide (70) synthesised by 
Bartlett and Jacobsen incorporating the phosphonamidate gave a K. of 6 nM at
pH 6.0,^^  ^ which is also the pH for the HIV protease assay.
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C T '
(70): Dipeptide Phosphonamidate Inhibitor of Carboxypeptidase A .
Bartlett contributed further to the area of phosphorus-containing inhibitors 
w ith the synthesis of (71), the most potent inhibitor yet for the zinc peptidase 
thermolysin, which had a of 9.1 nM.^^4
C T ' H  M I M
(71): Phosphonamidate Inhibitor of Thermolysin.
More relevant to HIV-1, McLeod et al. synthesised racemic d ipeptide 
phosphonam idates which showed K. values around 50 pM^^z (gee Fig. 2.4).
Com pared with other inhibitors in the literature (see Section 1.6), this is not 
outstanding inhibition, but that such a small molecule bound at all was 
interesting. It was observed that the methyl esters of the phosphonamidates also 
inhibited, in fact the symmetric Phe-Phe analogue inhibited better as the methyl 
ester. Furthermore, the inhibitors tested were racemic, so contained only a 
fraction of the preferred diastereomer. This all proved very encouraging for the 
successful use of phosphonamidates as inhibitors of the HIV-1 proteinase.
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O O
CF3OCNH. CF3OCNH.N 7 X  N
"  h' V n h .  "
o . R = (-) or CH3
Figure 2.4: McLeod et al.'s Dipeptide Inhibitors of HIV-1 Proteinase.
2.2.1. Solution-Phase Peptide Synthesis.
A num ber of excellent methods exist for making peptides in the solution 
phase, including the use of acid chlorides or carbodi-imide coupling methods. 
For our work, the mixed anhydride procedure was used (see Scheme 2.1).^50
Me /  Me" • •I?":oM© f ou ^  /I Me
O O
“ ’/ I .  J
Me
Scheme 2.1: Mechanism of the Mixed Anhydride Coupling 
Between (2S)-Isoleucine and iso~Butylamine.
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W hat is required in a coupling reaction is consistently high yields with no 
racémisation, which can be a problem where a base is employed. While 
methylamine gave a very rapid reaction, it also gave maximum racémisation. 
For this reason, N-methyl morpholine and iso-butyl chloroformate have been 
found to be the best combination.^^^ For some combinations of amino acids, the 
mixed anhydride method has been less useful, particularly in the case when one 
or both starting materials are barely soluble in THF; however, for our work, no 
such problems were encountered and its good yields and ease of use made it the 
method of choice for this part of the synthesis. The newly formed Boc-protected 
peptide, easily recognisable by its distinctive f-butyl peak at approxim ately 
1.5 ppm  in its ^H nmr spectrum, was then deprotected using hydrogen chloride 
gas in ethyl acetate.
This sequence of reactions was used to synthesise the initial target of (2S)-Pro- 
(2S)-Ile-NHiBu (72) and also (2S)-Phe-(2S)-Ile-NHiBu (73) which incorporates a 
degree of symmetry into the final inhibitor. These peptides could then be used 
in the key step, that of formation of the phosphonamidate.
2.2.2. Synthesis of Phosphinic Acid Esters.
To synthesise a phosphonam idate, it is vital that a reliable m ethod of 
obtaining its precursor is available. The classical route to the racemic 1- 
aminoalkyl phosphinic acids is by the addition of trialkyl phosphites to imines 
under rather harsh conditions.^®^ A milder method utilised the addition of the 
trim ethyl silyl esters of the phosphorous acids to i m i n e s . T h e  three 
component condensation of carbamate, aldehyde and phosphite has also proven 
useful.^5® This method provides an access to higher alkane phosphinic acids but 
it cannot be used in the synthesis of amino methane phosphinic acid. However, 
to complement this methodology, Oleksyszyn and Subotkowska developed a 
p a ra lle l syn thesis, again  using  a carbam ate and  p h o sp h ite , p lu s
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paraformaldehyde and acetic anhydride in glacial acetic acid.^^^ Yuan et al. 
provided a direct route to the phosphinic half acid half methyl ester using 
phosphorous trichloride and acetyl chloride, instead of the phosphite used 
above, followed by methanolysis.^^^ The role of the acetyl chloride is thought to 
be associated with the formation of a metaphosphate species which affords the 
monoesters in the subsequent alcoholysis.
The aminoalkyl phosphinic acids are also accessible via the equivalent 
phosphonous acids by an extremely facile oxidation step using aqueous bromine 
(see Scheme 2.2).^^^
HgNyPcOH H^N^^PcOH
R R
Scheme 2,2: Oxidation of Amino-Phosphonous Acid to 
Amino-Phosphinic Acid.
Virtually all the phosphonous amino acid analogues have been synthesised 
by addition of a suitable aldehyde to aminodiphenylmethane and 50 % aqueous 
hypophosphonous acid under reflux, followed by a deprotection step in aqueous 
hydrogen bromide.^^^ Fmoc-protected phosphonous acids have been used in 
obtaining the mono-O-alkylated phosphinic acids.^^^
To obtain the required phosphonate, a three step synthesis was used (see 
Scheme 2.3).
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NH
» OPh 
AOPh
CHO
(74)
II, III
NH O
(75) X = OMe
(76) X = OH
Reagents : (i) AcOH, 80 °C; (ii) NaOMe, MeOH, r.t.;
(in) 2 M NaOH, MeOH, r.t.
Scheme 2.3: Synthesis of Phosphinic Acid Methyl Ester.
Following the three-component coupling procedure of Oleksyszyn et 
using phenylacetaldehyde, triphenyl phosphite and benzyl carbamate in glacial 
acetic acid gave the diphenyl phosphonate (74) in 29 % yield (see Scheme 2.4).
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P h " ^ 0 " '^ N H 2  H
-HoO
+ H+
PhOPhO ^p
PhO^ '
O NH
4  OPh -PhOH
P h ' ^ O '^ N H ? "   ^ P h ^ O - ^ N H ^
H J ^ 5 ^ 0 P h  _ J 1 _  H ^ ^ O P h
P h ^  Ph''^
Scheme 2.4: Mechanism of Formation of Diphenyl Phosphonate (74).
TrflMs-esterification using sodium methoxide in m ethanol/^^ followed by 
removal of the phenol side-product by chromatography on silica, gave the 
dim ethyl phosphonate (75) in 67 % yield. An alternative procedure using 
potassium fluoride and 18-crown-6 in methanol was also employed^^^ but gave 
inconsistent yields. Finally, base hydrolysis gave the phosphinic acid methyl 
ester (76) in 77 % yield. The equivalent com pound (77), derived  from 
cyclohexylacetaldehyde, was also synthesied via this route.
i
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cy 'PxOH
(77): Cyclohexyfalanine analogue.
The phosphinic acid methyl esters were also synthesised using the one-pot 
procedure of Yuan and co-workers (see Scheme 2.5).^^^ The reaction did not 
proceed using phenylacetaldehyde, although it gave a 36 % yield w hen 
isovaleraldehyde was used, giving the Leu analogue (78).
O
NH (i) PCI3 , AoCl, O
0 °C \ OMe 
OH
(78)
Scheme 2.5: One-Pot Procedure For the Synthesis of 
Phosphinic Acid Methyl Esters.
2.2.3. In Vitro Testing.
Camp^^o took these two portions and coupled them using a modification of 
the method of B a r t l e t t . ^ H e  also deprotected and extended the compounds with 
Boc-Asn. These compounds were taken and tested against HIV-1 proteinase in 
vitro using a spectrophotometric assay which involved measuring the decrease 
in absorbance at 300 nm of the decapeptide K-A-R-V-Nle-F(N02 )-D-A-Nle-G- 
NH 2 as it is cleaved at the Nle-F(N0 2 ) peptide bond.^^^
The data obtained were analysed according to the method of Dixon.^^^ The 
assay was perform ed over a range of inhibitor concentrations and then 
1/in itia l rate was plotted against inhibitor concentration to give an IC50.
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Repeating this over a range of substrate concentrations gave a value for Ki; 
alternatively, it can be calculated via the following equation:
IC50
Ki = __________
(1+S/Km)
Initially, 1 % DMSO was used as a co-solvent; however, results obtained were 
poor and inconsistent. This was found to be due to an absorption by DMSO at 
300 nm; there have also been reports of DMSO acting as an inhibitor for HIV-1
proteinase.^67
The insolubility of these compounds in water proved to be a limiting step in 
determ ining their inhibition constants. Thus, an alternative co-solvent was 
sought to overcome this problem. Methanol was found to affect enzyme activity 
at 5 % concentration, although at concentrations of less than 2 % methanol, there 
was no appreciable loss in activity. Assaying using 1 % methanol proved 
satisfactory and a num ber of compounds were tested. These results are 
summarised in Table 1. Lineweaver-Burk double reciprocal plot of (79) showed 
the phosphonamidates to be competitive inhibitors of HIV-1 proteinase (see Fig. 
2.8).
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Figure 2.5: Lineweaver-Burk Double Reciprocal 
Plot For Phosphonamidate (79). (where 1/V2 = 0.2 % inhibitor, 
1JV4 = 0.4 % inhibitor, etc.).
The free phosphonamidate (68) had a relatively high IC50, most probably due 
to its anionic nature at the assay pH of 5.5. Therefore, our attention was turned 
to the methyl esters.
The target phosphonam idate methyl ester (69) had been separated into its 
indiv idual diastereom ers. It was expected that D-amino acid residues 
(equivalent to (S) configuration in a phospho-amino acid) w ould be poor 
inhibitors of HIV-1 proteinase. For example, Cushman et al. found that D-Phe at 
Pi' increases IC50 by 11-fold compared with the L-Phe epimer in a series of 
hydroxyethylenes.^^8 We observed a slight preference for the (R,R) diastereomer, 
with an IC50 of 30 pM compared with 80 pM for the (R,S) diastereomer, but the 
selectivity between different diastereomers was not all that marked (see Table 1).
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Why this contrast exists is not clear but it is likely to be due to a difference in the 
way the two different classes bind a n d / or interact within the active site.
,0CH3 Me. Me O Y
H \  Ho Mev ^MeO H V  H
(79) (80)
rMe Me
Mev ^Me
Me^  _Me
r  Me
H H
(82)
Me
Me
CONHg 
H M H
Me
(84)
Figure 2.6: Some Phosphonamidate Methyl Ester 
Inhibitors of HIV-1 Proteinase.
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Table 1. Summary of Inhibition data. 
Entry Compound Configuration IC50 (hWI)
Number at(Cap) HIV Proteinase 
inhibition
Antiviral
activ ity
1 B0C“N“F”PO2"P"l”NH“iBu
(68) (epimeric at C t^) 90 N.D.
Boc-N>F-[\|/]-P-l-NH-iBu
2 (69) (R, R) 30 453 (69) (R, S) 80 > 1 0 0
4 (69) (S, S) 100 > 1 0 0
5 (69) (S. R) 
Cbz-F-[\)/]-P-l-NH-iBu.
> 1 0 0 > 1 0 0
6 (80) (R, R) 5 37 (80) (R, S) 25 258 (80) (S, S) N.D. 259 (80) (S, R) N.D. > 1 0 0
1 0 Cbz-Cha-[i|/]-P-l-NH-iBu.
(81) (mix. 2  diast.) 16 8
11 Cbz-F-[\|;]-(2S)-F-l-NH-iBu.
(79) (mix. 4 diast.) 2 2
1 2 Cbz-Cha-[\]/]-(2S)-F-l-NH-iBu.
(82) (mix. 4 diast.) 1 513 H2N-F-[\}/]-(2S)-F-l-NH-iBu.
(83) (mix. 4 diast.) 30 2 0
14 Boc-N-F-[i|f]-(2S)-F-l-NH-i Bu.
(84) (mix. 4 diast.) 100 > 1 0 0
15 Qua-N-F-[\|r]“(2S)"F-l-NH-iBu.
(85) (mix. 4 diast.) 45 50
16 Qua"N“Cha-[\|/]"P"l"NH-iBu.
(86) (1 diast. unknown) 2 0 1517 CbZ“F“[\j/]“(2R)-F"l‘’NH-iBu.
(87) (mix. 4 diast.) 1 N.D.18 Cbz-F-[\j/]-G“l-NH“iBu.
(88) (mix. 4 diast.) >30 N.D.19 Cbz-F-[\j/]-(2S)-F-NH-iBu.
(89) (mix. 4 diast.) 40 N.D.
2 0 Cbz-F-[\i/]-(28)-F-(OMe).
...... (90).................. (ml .^ 4 diast,) , ................ 100 .. too
* Values of IC50 are estimated to be accurate to within ± 10%. 
[\j/] = -P0(0CH3)-.
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HgNOC'
Ô (85) Me
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O H Î
HgNOC
Me. Me
J  " t ”
: s ^ K ï
[ Me 
Me
(87)
o _  Me. ,  Me O Y
H H Ü, H % H 
[ Me 
Me
(88)
N
H H
(89)
H H
(90)
o
Figure 2.7: Further Phosphonamidate Methyl Ester 
Inhibitors of HIV-1 Proteinase.
The Cbz-protected analogue (80), which is a precursor of the full inhibitor (69) 
was also tested and this displayed greater potency. It is now known that the Boc
 ^ - ■ ' ' ' " ...
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group interacts unfavourably when put in the P3 position and that w ith this 
group deleted then the interactions are correspondingly more favourable. The 
various diastereomers tested also showed the lack of selectivity that the longer 
inhibitors did, with the (R,R) isomer possessing an IC50 of 5 pM and the (R,S) 
isomer having an IC50 of 25 pM (see Table 1). The (2S)-Phe-(2SHle-NHiBu 
peptide (73) was incorporated into the inhibitors (79) and (84) and this showed a 
similar trend between the longer and shorter compounds. It was also more 
potent; as a m ixture of diastereom ers it had an IC50 of 2 pM. The 
cyclohexylalanine analogue was also incorporated and was found to be a good 
replacement for Phe, with (79) and (82) displaying very similar IC50 values.
0.8 -
0.6 -
>
0.4 -
0,2 -
0,0
•4 •2■6 2 4 6 a 10 120
I /^ iM
Figure 2.8: Plot of 1/Initial Rate Against Inhibitor 
Concentration For Phosphonamidate (79).
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1
0
4 2 2 4 6 80
I / \ i M
Figure 2.9: Plot of 1/Initial Rate Against Inhibitor 
Concentration For Phosphonamidate (82).
This series of compounds have also been evaluated in cells by D. Kinchington 
at S t Batholomew's Hospital in London (see Table 1). Comparison with our in 
vitro data showed a remarkable correlation between the in vitro and in vivo 
values. The reason for this correlation is not clear and it is tempting to suggest 
that it is due to some property of the phosphonamidate methyl ester that allows 
for highly efficient cell-uptake.
The full details of this work have been published.^
2.2.4. Incorporation of Piperidine-2-Carboxylic Acid
As an alternative to Pro at P i ', piperidine-2-carboxylic acid (91) was 
incorporated into the peptide. When it replaced Pro in a substrate, the resulting 
peptide was an inhibitor with a Ki of ~ 1 and the hydroxyethylamine Ro-31- 
8959 (28) contains the somewhat similar decahydroquinoline residue in the same 
position.
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However, enantiom erically pure piperidine-2-carboxylic acid (which is 
known commercially as pipecolinic acid) is extremely expensive and so efforts 
were made to obtain the single enantiomer by other means.
The racemic pipecolinic acid is readily available and the peptide (2R/S)-Pip- 
(2S)-Ile-NHiBu was prepared via a similar protocol to the other peptides. It was 
hoped that separation of the diasteromers so formed would be possible; however, 
by t.l.c. in a variety of solvent sytems, there was only very limited resolution at 
best.
Kisfaludy et a l  dem onstrated the cyclisation of (2S)-lysine to give (2S)- 
pipecolinic acid using sodium nitroprusside under strict pH control (see Scheme 
2 .6).:70
OH
NHa
Na2[Fe(N0)(CN)s] 
pH 9.5
:
OH
H
(91)
Scheme 2.6: Preparation of (2S)-Pipecolinic Acid From (2S)-Lysine.
When this procedure was followed, it was evident from the colour change in 
the reaction vessel that some kind of reaction had taken place. However, it 
proved impossible to separate the required product from the inorganic side- 
products, either by extraction into an organic solvent or by silica or fluorosil 
colum n.
We turned instead to the resolution procedure of H ardtm ann et al. (see 
Scheme 2.7).^^  ^ The racemic amino acid and (2S,3S)-tartaric acid were dissolved 
in methanol, resulting in the formation of the tartrate salt. The (2S)-pipecolinic- 
(2S,3S)-tartrate precipitated out and could be collected by filtration. After drying, 
the purity of this salt was checked by melting point (195-196 °C, lit.^^^ 195-196 °C) 
and optical rotation (ao = -20 (c 2 in H2O), lit.^^i _2i  (c 2 in H 2O)),
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OH
Scheme 2.7: Resolution of (2R/S)-Pipecolinic Acid 
Using (2S,3S)-Tartaric Acid.
The free acid was obtained by passing the tartrate salt through an IR-120H 
Amberlite ion exchange column in its H+ form, under which conditions the 
positively charged pipecolinic ion remains on the column and the tartrate anion 
is washed off. Elution with 10 % ammonia solution then yielded the pure (2S)- 
pipecolinic acid in 57 % yield (m.p. 268-270 °C, lit^^i 270-272 °C, a o  = -23 (c 1.5 in 
H2O), lit.^71 -26 (c 1.5 in H2O ). Washing the column thoroughly w ith distilled 
water was found to be necessary to ensure that no tartrate remained on the 
colum n.
The amino acid so obtained was N-protected using a Boc group and coupled 
to (2S)-Ile-NHiBu.HCl (92) using the mixed anhydride method. Subsequent 
deprotection yielded the required dipeptide amide (93).
H O
(93): (2S)-Pip-(2S)-Ile-NHiBu,
The crucial step of the synthesis was to couple the phospho-amino acid to the 
dipeptide amide (93), which was achieved via the phosphonic acid chloride. 
Earlier work had shown that the reaction does proceed very well, although steric
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factors are very important to the overall yield.^^^ It has been found that both the 
(2S)-Phe-(2S)-Ile-NHiBu (73) and the original peptide (2S)-Pro-(2S)-Ile-NHiBu 
(72) couple satisfactorily, in approximately 50 % yield. However, the coupling of 
the (2S)-Pip-(2S)-Ile-NHiBu (93) with the phosphophenylalanine analogue (76) 
proceeded very poorly, even at elevated temperature. From models of the 
reactants, we found that in the proline case, the strain of the ring pulls back the 
peptidic side chain, and keeps it out of the way so that the reaction could proceed. 
However, in the six-membered ring of the pipecolinic acid, this strain is released, 
and the (2S)-Ile-NHiBu causes severe steric interaction with the phospho-amino 
acid, making the coupling a slow and difficult process. (2S)-pipecolinic acid 
methyl ester was prepared in an attempt to reduce this unfavourable interaction, 
but even this was enough to cause very little product to be formed.
2.2.5. Extending the Chain.
The methyl group on the phosphonamidate methyl ester should cause some 
unfavourable steric interactions in the active site. However, in vitro assays have 
show n that they have equal to or greater potency than  the free 
phosphonamidate. While there may be something of an exchange of one bad 
interaction for another in this, it was decided to investigate the scope for 
extending this chain to ethyl or larger groups.
cr ' l i ï - i i j - .
(94): Phosphonamidate Ethyl Ester.
Chapter 2: Results and Discussion 69
a
(95): Phosphonamidate n-Propyl Ester.
The ethyl phosphinic acid ester (96) was prepared in an almost identical 
fashion to the methyl analogue, in a slightly lower overall yield of 36 %. The n- 
propyl analogue (97) was also available by this route, except that sodium hydride 
rather than sodium metal was used to generate sodium propoxide and the base 
hydrolysis to the phosphinic acid ester proceeded in very poor yield.
"o h  I "OH
(96): Ethyl Phosphinic Acid Ester. (97): n-Propyl Phosphinic Acid Ester.
However, attempts to synthesise the trifluoroethoxy analogue (98) by reaction 
of the d ipheny l phosphonate w ith  trifluoroethoxide (produced  from  
trifluoroethanol and sodium hydride) in THF were unsuccessful (see Scheme 
2.8).
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A  °
°  CF3CH2OH.
NaH.THF
NH OPlï
(98)(74)
Scheme 2.8: Attempted Synthesis of Trifluoroethoxy Analogue x9S).
An alternative route was investigated, using the methodologies of Dingwall^^i 
and Dumy 6^2 (gee Scheme 2.9). The diphenylmethylphosphonous acid (99) was 
syn thesised  by adding  phenylacetaldehyde to a refluxing m ixture of 
aminodiphenylmethane and 50 % hypophosphonous acid. This is thought to 
proceed via an imine to which a hypophosphite anion adds. Addition of 1 M 
HCl was found to improve yields by suppressing a competing reduction of the 
imine by the hypophosphite. The diphenylm ethyl group was rem oved by 
treatm ent w ith aqueous hydrogen brom ide, followed by treatm ent with 
propylene oxide to give the free phosphonous acid (100) in 83 % yield.
■ a  -r
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Ph
DaH
XP h ^ O ^ N H  O Ph"" "O'" "NH Q
H, III, IV
ci^GR V, vi u . i— p^OH
^ O H ^ * --------- .  I H
II
(102) (101)
Reagents: (i) H3PO2, 1 M HCl, A; (ii) 48 % aq. HBr; (iii) Propylene oxide,
EtOH; (iv) PhCHzOCOCl, 5 % NaHCOs; (v) DCC, ROH, CH2CI2; 
(vi) aq. Br2.
Scheme 2.9: Synthesis of Chz-Amino-Phosphinic Acid Esters 
via Phosphonous Acid.
The amino group was re-protected with a benzyloxycarbonyl group and then a 
DCC coupling of the phosphonous acid with trifluroethanol was attempted. A 
product was isolated that possessed the expected CH2 singlet at 4.9 ppm in its IH  
nmr spectrum but no CF3 signal could be observed by i^C nmr spectroscopy.
The phospho-amino acids so obtained were coupled to (2S)-Phe-(2S)-Ile- 
NHiBu (73) by forming the phosphoryl acid chloride using thionyl chloride in 
dichloromethane, followed by addition of the peptide at 0 °C, along with 2.5 
equivalents of triethylamine as an HCl s c a v e n g e r . ^ ^ o  During the acid chloride 
formation, it was found to be im portant to flush the flask with nitrogen to 
remove the acidic gases formed during the reaction, as this flushing procedure
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led to much cleaner final products. The resulting inhibitors could be directly 
compared with the methyl ester (79).
The phosphonamidate ethyl ester (94) gave an IC50 of 4.5 pM (see Fig. 2.10). 
Thus there is a slight drop in potency, not surprisingly, although the drop is not 
especially great. There is evidently some leeway for incorporation of functional 
groups onto the phosphonamidate and this is explored further in section 2.4.
1.0
0.8
0.6
0.4
0.2
0.0 1 0 6 2 2 6 1 41 0 1 8 22
I /pM
Figure 2,10: Plot of 1/Initial Rate Against Inhibitor Concentration for 
Phosphonamidate Ethyl Ester (94).
2.3. Interlude - Benzoin Inhibitors of HIV-1 Proteinase.
As has already been noted, peptidic compounds rarely make good drugs. 
Ideally what is required is a simple and easily accessible non-peptide which 
displays potent anti-viral activity and low toxicity. While it is difficult to predict 
the behaviour of inhibitors in vivo, it should be possible to incorporate the 
features that make a potent inhibitor into a low molecular weight molecule 
which hopefully will lead to the required biological profile.
An interesting lead compound in this search is the benzoin (103). This has a 
high degree of C2 symmetry to reflect that in the enzyme, which is even greater if 
within the active site, the benzoin can enolise (see Fig. 2.11).
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O OH
(103): Benzoin Inhibitor of HIV-1 Proteinase 
HQ O
H .
HO OH
Ar ArAr Ar 
Figure 2,11: Enolisation of Benzoin.
The compound is readily available in a three step synthesis from m-nitro- 
benzaldehyde.
.CHO ^  CHO
NO, NHg
(104)
CHO
m
(103)
Reagents:
O(105)
(i) SnClz, cone. HCl; (ii) PhCHiOCOCl, 2 M NaOH;
(iii) 3-Ethyl-5-(2-hydroxyethyl)-4-methyl-thiazolium 
bromide, EtgN, EtOH, reflux, 40 h.
Scheme 2.10 Synthesis of 3, 3 ’-Di-[(Benzyloxycarhonyl)-amino]-benzoin.
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Stannous chloride reduction in concentrated hydrochloric acid gives m- 
aminobenzaldehyde (104)372 ^ s  this can polymerise if allowed to stand, this was 
im m ediately N -protected using benzylchloroformate in sodium  hydroxide 
solution. This was achieved in 51 % overall yield after column chromatography. 
The final step is a benzoin condensation, in which two molecules of starting 
material condense with each other, catalysed by a thiazolium s a l t^73 (see Scheme 
2.11). This reaction is very much substrate dependent since some aldehydes 
make good acceptors and some good donors, w ith benzaldehyde itself 
som ewhere in the middle. After 40 hours reflux, follow ed by column 
chromatography, the reaction gave only a 25 % yield of final product.
C + M -
HO HO
H3C —CH3
H .^ A r
N D o n o r^HqC ^ V--CH3
HqC
OH
o  ^ A r '
Co H
HqC,
H3C Ar-
HO H
Acceptor
Scheme 2,11: Mechanism of the Benzoin Condensation.
The benzoin was tested in vitro and was found to possess an IC50 of about 
7 jj-M (see Fig. 2.12).
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Figure 2,12: Plot of Ijlnitial Rate Against Inhibitor 
Concentration for Benzoin (103).
Although no further work has yet been done on this type of compound, it 
makes for an interesting lead compound and scope exists for considerable 
improvement in potency in a future study.
2.4. Bicyclic Phosphorodiamidates.
As part of the ongoing phosphonamidate program, a new design of inhibitor 
was proposed. This originated partly from wanting a non-peptidic target and also 
from molecular modelling that showed that the flap structural water molecule 
could be displaced.
The cyclic ureas (61) and (62) (see Section 1.6.8) have since shown that the 
hypothesis was a feasible one.^^^ Other desirable design features included a 
degree of C2 symmetry and the introduction of a strained system as this would 
only be able to adopt a minimal num ber of conformations, which should 
enhance binding. Such a molecule could also find use as an active site probe. 
H aving show n that it was possible to extend the ester chain in the
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phosphonam idates, ex trapolation  of this led to the design of the 
phosphorodiamidate (106).
9
Ph.. ' "W i  L"*' ^ Ph
OH
(106): Bicyclic Phosphorodiamidate.
Molecular dynamics calculations on (106) by J. Wilkie showed that it should 
take up a skewed conformation in the active site of the enzyme (see Figs. 2.13 and 
2.14). The OH group positions itself between the catalytic Asp 25 and 25' whereas 
the P = 0  forms a strong hydrogen bond interaction w ith on of the flap He's 
(approx. 2-2.5 Â apart), but it is relatively distant (> 6 Â) from the other flap He 
(see Fig. 2.13). Despite this, the benzyl groups seem to make a good hydrophobic 
interaction in the Pi and P i' pockets (see Fig. 2.14). This shows that the molecule 
won't take up a strictly C2 symmetric conformation, but the results of Kempf and 
co-workers (see Section 1.6.7) have shown that it is virtually impossible to do 
this. It otherwise seems to be a good fit, but whether it will be able to hold both 
flaps closed, or whether holding one flap closed is enough, remains to be seen.
A proposed synthesis of this compound is shown in Scheme 2.12.
- I
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0 0 ONH2 X X XH O ^  HN O _ i i ^  HN O _ Ü L ^  H N ^ p
(107) (108) (109)
iv
. L    X
Ph
HgN ° H  HjN \ , , _ ^ P h  HN \ , , , ^ P h
(112) H
(111) (110)^vlil, Ix
O O
o Y —2-* - Yo
NHa OH
(113) (106)
Reagents: (i) CO(OEt)2, K2CO3, 130 °C; (ii) (COCl)2, DMSO, EtsN, CH2CI2;
(ui) H2N -N H 2.H2O, CH2CI2; (iv) BnMgBr, THF, - 78 °C; (v) H2, 
Pd/C, MeOH; (vi) CH3CHO, p-TsOH, PhCHs; (vii) UAIH4, THF; 
(viii) PCI3, EtsN, CH2CI2, - 20 “C; (ix) m-CPBA, CH2CI2; (x) NaN0 2 , 
HCl, H2O.
Scheme 2,12: Proposed Synthesis of Phosphorodiamidate (106).
The nitrogen and one oxygen of frfs-hydroxym ethylam inom ethane were 
protected as the oxazolidinone (107) by the method of Evans et al. using diethyl 
carbonate and potassium carbonate in 76 % yield.^^  ^ Efficient mechanical stirring 
of this reaction is vital since the mixture quickly becomes too thick for a 
magnetic stirrer to operate effectively.
(114): Diacetal Derived From Tris Hydroxy methyl Amino Methane.
   - -   ' '
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Oxidation to the di-aldehyde (108) proved problematic. The starting material 
was highly insoluble in organic solvents and initial efforts used a variety of 
chroma te oxidation p r o c e d u r e s . W h i l e  the colour change in the reaction 
vessel indicated some kind of reaction had taken place, no product could be 
extracted from the reaction mixture. The reason for this could be that the di­
aldehyde is sufficiently polar that it is very difficult to remove it from the metal 
surface or from an aqueous solution. nmr spectroscopy of an aqueous layer 
indicated a peak corresponding to the aldehyde CH at 8.4 ppm. However, all 
attempts to isolate or extract this compound, including saturation of the aqueous 
layer with sodium chloride, resulted in failure. Although highly polar, the diol 
was sparingly soluble in DMSO and so a Swern oxidation was a t t e m p t e d . ^ B y  
t.l.c., a new spot that was positive to both permanganate and Brady’s reagent was 
observed; however, all attempts to isolate the di-aldehyde resulted in failure.
The main problem seemed to be the diol's insolubility, so attempts to increase 
its organic solubility were made by benzylating the nitrogen using benzaldehyde, 
which has been previously demonstrated on serine.^^? Mass spectrometry on 
the product of this reaction showed a peak at 298 a.m.u., which corresponds to [M 
+ H]+ of the di-acetal (114). In an attem pt to form the m ono-N ,0-acetal 
selectively, only one equivalent of benzaldehyde was used but this also led to the 
di-acetal.
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Baker and Condon reported a series of hydroxyethylene inhibitors of renin 
and HIV-1 proteinase which were relevant to our own work,^^® They used a one- 
pot procedure, taking a diol, forming a di-aldehyde in situ, then reacting this 
with N,N-dimethyl-hydrazine to form a tetra-methyl-di-hydrazone. Grignard 
addition to the dihydrazone resulted in the formation of a single dihydrazine, 
thus displaying the extremely good diastereoselectivity in this reaction.
This protocol was adapted for use with the oxazolidinone-diol (107) (see 
Scheme 2.13). It was essentially a Swern oxidation followed by addition of N,N- 
dimethyl-hydrazine and anhydrous magnesium sulfate at room temperature. In 
order to solvate the starting material, it was necessary to perform the Swern 
oxidation in a 40:60 mixture of DMSO:dichloromethane at -50 °C; at any lower 
temperature than this, the solution froze. The mixture was allowed to warm to 
room temperature, the hydrazine and magnesium sulfate added and the mixture 
stirred overnight. Purification by column chromatography yielded the tetra- 
methyl-di-hydrazone (115) as an orange oil in 47 % yield.
X
HN O
r f - '
OH
(107)
1
HN O
(108)
1HN O
Nf! ^  Me  N - N .
Me
Me
N'Me
(115)
Reagents: (i) (COCDz, DMSO, EtsN, CH2CI2, - 50 °C -> r.t.;
(ii) MezNNHz, MgS0 4 -
Scheme 2,13: Preparation of Di-Hydrazone (115).
Grignard addition was then attempted, but this led to a mix of products. It 
was suggested that the conditions were too harsh, thus the milder cuprate was 
tried in its p l a c e . ^ ^ 9  However, there was still no sign of the required product; it is 
possible that this system is too sterically demanding for the required &fs-addition
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to take place; in Baker and Condon’s inhibitors, there were an extra two carbons 
between the two reacting centres.
In order to get around this problem, a simpler analogue (116) was devised. 
This meant that the phosphorodiamidate moiety could still be studied as an 
inhibitor of HIV-1 proteinase.
OII
Ph PhVOH
(116): Simplified Phosphorodiamidate.
This could be accessible by oxidation of the diol to the di-acid, followed by 
formation of the amide, reduction with lithium aluminium hydride and, finally, 
cyclisation (Scheme 2.14).
Oxidation of the diol (107) to the diacid (117) was thus attempted. Again there 
seemed to be a good deal of difficulty in extracting the product from the reaction 
m ixture, either from chrom ate oxidative procedures^ or using basic 
pe rm an g an a te .^ H o w ev er, acidic permanganate^^ 2 seemed to give the required 
product by ^H and ^^C NMR spectroscopy. However, mass spectrometry did not 
give the required molecular ion peak and attem pted . derivatisation w ith 
diazomethane to give the di-methyl di-ester further indicated that it was not the 
di-acid at all, although the identity of this product has eluded determination.
"  '  r n - -   :.t '— L ----^ '  - i . t t  -,
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HO
I
HN O 
(107)
1
HN O \ 7
QQg|_|
(117)
HN
NH
Ph
O
Ph'
(118)
V
OH
(116)
Ph
iv, V, vi P h '
NH,
Ph
OH
(119)
Reagents: (i) KMnO^, aq. NaOH, acetone; (ii) NMM, Me2CHCH2 0 C0 Cl,
BnNH2, THF, - 15 °C; (iii) UAIH4, THF; (iv) PCI3, EtsN, CH2CI2,
- 20 °C; (v) m-CPBA, CH2CI2; (vi) NaN0 2 , HCl, H 2O.
Scheme 2,14: Proposed Route to the Simpler Phosphorodiamidate (116).
Therefore, an alternative synthesis from diethyl malonate (120) was proposed 
(Scheme 2.15). Knoevenagel condensation by the m ethod of Bachman and 
Tanner gave diethyl methylene malonate .^ 3^ This is a potent Michael acceptor so 
it was immediately epoxidised by the method of Foucaud^^^ using 10 % sodium 
hypochlorite solution on an alumina surface to give (121) in 35 % overall yield. 
Opening the epoxide with sodium hydroxide was ineffective but with sodium 
acetate, the reaction proceeded s m o o t h l y , ^ 8 5  giving rise to a new peak in the ^H 
nm r spectrum at 2.1 ppm, corresponding to the acetate, and a shift in the CH2 
signal from 3.2 ppm in the epoxide to 4.6 ppm.
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X I
(120)
►  EtO OEt
(121)
Ph'
OH
(123)
Ph EtO OEtIV
OH
OAc
Ph'
OH
Ph
VI, VII
(122)
O II
Ph^ N" 'P h
OH V
(124)
OH
(116)
Reagents: (i) Paraformaldehyde, Cu(OAc)2, KOAc, AcOH, 90 °C; (ii) Neutral 
alumina, CH3CN, 10% NaOCl, r.t.; (iii) NaOAc, AcOH, 90 °C;
(iv) BnNH2, EtOH, A; (v) LiAlH4, THF, r.t.; (vi) PCI3, Et^N, THF,
- 20 °C; (vii) m- CPBA, CH2CI2, 0 °C -> r.t..
Scheme 2,15: Proposed Synthesis of N,N'-Dibenzyl 
Phosphorodiamidate (116).
To obtain the diamide, the malonate derivative (122) was refluxed in freshly 
distilled ethanol with an excess of benzylamine.i®^ This had worked well when 
used w ith diethyl malonate, giving N,N '-dibenzyl m alonam ide as a white 
crystalline solid, so no problems were anticipated. Unfortunately, although the 
expected reaction did occur, so did a deformylation, as detected by the appearance 
of a CH signal at 4.5 ppm in the  ^H nmr spectrum. This was confirmed by an
>
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APT experiment in the nmr spectrum which showed a down peak at 73 ppm.
The method of Seebach, which is at room temperature, was also tried^^^ but gave 
similar results.
It appears to be that the retro-aldol reaction is facile for the diester. Since the 
acetate is the most accessible of the three esters, it will be this that will react first.
Due to the stability of the malonate anion (125), this molecule can then 
deformylate. If the opening of the epoxide and amide formation were switched, 
then the acetyl group will remain intact and thus there will be no opportunity 
for a deformylation to take place. Also, it could be that with a diamide instead of 
a diester, the retro-aldol will not be so facile and the deformylation will not take 
place.
11
(125): Diethyl Malonate Enolate,
Therefore, the epoxide diester (121) will be refluxed in ethanol with an excess 
of benzylamine to give the epoxide diamide (126) and then this can be treated 
with sodium acetate in acetic acid at 90 °C to give the acetate diamide (127). |
O O
Ph" ’ PhH / ) o  H
(126): N, N'-Dihenzyl-Epoxymethylene Malonamide.
O O
Ph" N N Ph
H /  OH H 
OAc
(127): AT, N'-Dihenzyl-Acetoxymethyl-Hydroxy-Malonamide.
A
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Reduction of this compound should give the dihydroxy-diamine (124), which 
can then be cyclised using phosphorus trichloride followed by m-CPBA oxidation 
to give the phosphorodiamidate (116). This part of the synthesis is being carried 
out by others in our group.
To obtain the original target, it was initially thought that a sim ilar 
methodology could be used (see Scheme 2.16).
R R
(128)
"'■'N N '" '
R IV
OH
OAc
(131)
O O 
(129)
0 + 0
OAc
(130)
p OH 
OH 
(132)
VI, VII
OH
(133)
Reagents; (i) Paraformaldehyde, Cu(OAc)2, KOAc, AcOH, 90 °C; (ii) Neutral 
alumina, CH3CN, 10% NaOCl, r.t; (ill) NaOAc, AcOH, 90 °C;
(iv) R'NH2, PhCHs, cat. p-TsOH, A; (vi) L1A1H 4, THF, r.t.;
(vü) PCI3, EtgN, THF, - 20 °C; (viii) m-CPBA, CH2CI2, 0 °C -> r.t.;.
Scheme 2.16: Proposed Route to the Generalised Phosphorodiamidate (133).
M
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The 1,3-diketone is available by cuprate additionnas onto m alonyl 
dichloride.ns9 However, some difficulty was encountered with the Knoevenagel 
condensation. Alternatively, the diester (1 2 2 ) could be used, as there are a 
num ber of procedures that add organometallics to esters to give ketones.ns7,i90 
The simplest of these is that of Kikkawa et al, in which a Grignard reagent is 
added to the ester in the presence of triethylamine.n^Oa This was tried using 
diethyl cyclobutane-1,1-dicarboxylate as a model and gave a t.l.c. spot that was 
positive to Brady's reagent. However, upon isolation, ^H nm r spectroscopy and 
mass spectrometry revealed it to be the keto-ester (134).
OEt
(134): Keto-ester Derived From Diester,
Adjustm ent of the conditions of the Grignard addition may allow for the 
required diketone to be obtained. Unfortunately, there was not sufficient time to 
complete this part of the study. This will also be continued by others in our 
group. This can then be applied to the synthesis of diketone (130), leading to the 
substituted phosphorodiamidate (133).
CHAPTER THREE
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3.0. Experimental
NMR Spectra were recorded on a Bruker AM-300 F.T. spectrom eter (^H,
300 MHz; ^^C, 75 MHz; 121.5 MHz) and a Varian Gemini F.T. spectrometer 
OH, 200 MHz; ^^C, 50 MHz). High field NMR spectra were obtained on a 
service basis at the University of Edinburgh (^H, 600 MHz; ^^C, 150 MHz;
243 MHz) and the University of Warwick (^H, 400 MHz; ^^C, 100 MHz). ^H S
NMR spectra were referenced on chloroform, methanol or DMSO, ^^C NMR "
spectra were referenced on chloroform, methanol or DMSO and ^^P spectra on 
external H 3PO4. NMR spectra are described in parts per million downfield 
shift from TMS and are reported consecutively as position (ôy or 6^.), relative
integral, multiplicity (s-singlet, d-doublet, t-triplet, q-quartet, m-multiplet, d of 
d-doublet of doublets and br-broad), coupling constant Qx,y applicable) and 
assignment. Infrared spectra were recorded using a Perkin Elmer 1420 ratio 
recording spectrometer and a Perkin Elmer 1710 f.t. i.r. spectrometer. The 
samples were prepared as Nujol mulls or thin films between sodium chloride 
discs. Absorption maxima are given in wavenumbers (cm"^) relative to a 
polystyrene standard. UV spectra were recorded on Pye-Unicam SP8-500 or 
SP8-100 spectro-photom eters. M elting points were m easured  using 
electrothermal melting point apparatus and are uncorrected. Optical rotations 
were measured on an Optical Activity Ltd. AA-100 polarimeter using 10 cm 
path length cells at room temperature. Mass spectra were recorded on a Kratos 
MS50 and obtained on a S.E.R.C. service basis at the University of Swansea 
using a VG ZAB E. Major fragments are given as percentages of the base peak 
intensity. Where appropriate, all solvents and reagents were freshly distilled 
prior to use. THE and ether were distilled from sod ium / benzophenone 
under a nitrogen atmosphere; DMF and CH2CI2 were distilled from CaH2 - 
Flash chromatography was performed according to the procedure of StilF^^ 
using Sorbisil C60 (40-60 pm) silica gel. Analytical thin layer chromatography 
was carried out on 0.25 mm precoated silica gel plates (MN SIL G /U V 254) and |
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com pounds were visualised by UV fluorescence, iodine vapour, ethanolic 
phosphomolybdic acid, aqueous potassium permanganate, Brady's reagent or 
ninhydrin .
Boc-(2S)-isoleucine-isobutylamide (135).i^o
BoC“(2S)“isoleucine (4.62 g, 20 mmol) was dissolved in anhydrous THE 
(100 cm^), N-m ethylmorpholine (2.18 cm^, 20 mmol) was added and the 
solution cooled to -15 °C. Isobutylchloroformate (2.72 cm^, 20 mmol) was 
added with stirring. The solution was left for 5 min. Isobutylamine (1.99 cm^, 
20 mmol) was added at -15 °C and the solution left for 5 min. The solution 
was allowed to warm  to room tem perature over a further 15 min. The 
hydrochloride salts were filtered off and the THE removed under reduced 
pressure to yield a white solid which was recrystallised from m ethanol/ water 
or ethyl acetate/ light petroleum (4.85 g, 85%). m.p. 158-160 °C (lit.^^o 158- 
160 °C). m/z (Found: [M + H]+ 287.2335. requires 287.23347); [a]o
-27.1 (c 1 in MeOH); v ^^x  (Nujol) /cm -: 3335 (NH), 1682 (Urethane CO) &
1655 (Amide CO); 5h (200 MHz, C^HClg) 0.9 (12H, m, CHg's (a,b,c)), 1-1.25 (IH, 
m, CH (iBu)), 1.42 (9H, s, Boc), 1.7-1.9 (3H, m, CHg & CH (lie)), 2.98-3.20 (2H, 
m, CH2 (iBu)), 3.89 (IH, d of d, /  7,9, a-CH), 5.19 (IH, d, /  8 .6, NH (urethane)) 
& 6.10 (IH, t, /  5, NH (amide)), ôc (50.3 MHz, C^HClg) (12.0 (ÇH3 (a)), 16.2 
(ÇH3 (b)), 21.0 (ÇH3 's (c)), 25.2 (ÇH2 (He)), 28.9 (Boc CH3's), 29.0 (CH3 (c)CH), 37.9 
(CH(CH3 (b)), 47.4 (CH 2 (iBu)), 60.2 (a  CH), 80.8 (C (C H 3 )3) & 156.6 (CO
1
•• ...   L' - ' ..........
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urethane), 172.2 (CO amide); m/z (Cl) 287 ([M + H]+, 8 %), 231 (48, [M + H - 
HaCCCH2]+), 213 (42, [M + H - H3CCCH2 - H 201+) & 187 (100, [M + H - Boc]+).
(2S)-isoleucine-isobutylamide hydrochloride (92).'S®
HCl gas was bubbled into ethyl acetate (150 cm^) at 0 °C for Ih. Boc-(2S)- 
isoleucine-isobutylam ide (135) (4.94 g, 17 mmol) was added to the acidic 
solution and left for 1.5 h. at room temperature. The solvent was removed 
under reduced pressure to yield an off-white gummy solid (3.45g, 90%). m/z 
(Found: [M + H]+ 187.1810. CJ0H23N 2O requires 187.1810); (Nujol) /cm*i
3200 (NH), 1665 (CO) & 1558 (Amide H); 5h (200 MHz, d ^-DMSO) 0.9 (12H, m, 
CHg's), 1-1.25 (IH, m, CH (iBu)), 1.5-1.9 (3H, m, lie CH2 & CH), 2.84 & 3.07 (2H, 
m, CH2 (iBu)), 3.65 (IH, t, /  4.8, He a-CH), 8.31 (3H, s, NH3+) & 8.64 (IH, t, /  5.4, 
iBu NH); ôc (50.3 MHz, d ^-DMSO) 12.02 (ÇH3 (a)), 15.17 (CH, (b)), 20.89 (ÇH3 's 
(0), 25.42 (ÇH2 (He)), 28.69 (iBu CH), 37.19 (CHiCHj (b)), 47.86 (ÇH2 (iBu)), 58.48 
(a CH) & 168.91 (CO amide); m/z (El) 187 ([M + H - HC1]+, 100%), 86 (41, [M + 
H - HCl-C(0)NHiBu]+).
—
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Boc-(2S)-prolyl-(2S)-isoleucyl-isobutylamide (136).:^^
A O —
M ec
M e
Boc-(2S)-proline (430 mg, 2 mmol) was dissolved in anhydrous THE (20 cm^), 
N-methylmorpholine (218 pi, 2 mmol) was added and the solution cooled to 
-15 °C. Isobutylchloroformate (272 cm^, 2 mmol) was added with stirring and 
the solution left for 5 m in at -15 °C. (2S)-lle-NH-iBu hydrochloride (92) 
(450 mg, 2 mmol) and N-methylmorpholine (218 pi, 2 mmol) were dissolved 
in THE and added to the cold solution. The reaction was left at -15 °C for 
5 min and a further 15 min at room temperature. The hydrochloride salts 
were filtered off and the THE removed under reduced pressure to yield a 
white solid which was recrystallised from ethyl acetate/ light petroleum  
(698 mg, 91%), m.p. 126-128 °C (lit.:50 126-128 °C); m/z (Found: [M + H] + 
384.286. C20H38N3O4 requires 384.2862); [alp -85.5° (c 1 in MeOH); V^ax (Nujol)/ 
cm": 3292 & 3089 (NH str.), 1706 (CO str. (urethane)), 1645 (CO str. (amide)) and 
1553 (NH bend); 6^  (200 MHz, C2HCI3) 0.85 (12H, m, CH3's (a,b,c)), 1.05 (IH, m,
1 X CH2 (lie)), 1.40 (IH, m, 1 x CH2 (lie)), 1.45 (9H, s, Boc), 1.7-2.3 (6H, m, CH 
(iBu), CH (He) & CH2's (2) & (3) (Pro)), 2.85-3.2 (2H, m, CH2 (iBu)), 3.45 (2H, br, 
CH2 (1) (Pro)), 4.25 (2H, br, a  CH's) and 6.67 & 6.94 (2H, br, NH's); 0^ (50.3 MHz, 
C2HCI3) 12.0 (ÇH3 (a)), 16.0 (ÇH3 (b)), 20.8 (ÇH3 's (c)), 24.6 (CH2 (2) Pro), 25.2 
(ÇH2 (He)), 28.6 (CH (iBu)), 28.7 (Boc CH3 s^), 29.3 (ÇH2 (3) Pro), 36.4 (CH (He)), 
47.4 (ÇH2 (iBu)), 47.7 (ÇH2 (1) Pro), 58.6 ( a C H  (He)), 61.0 (a  CH (Pro)), 81.3
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(QiCHshl  156.2 (CO urethane), 171.4 (CO (lie)) and 172.4 (CO (Pro)); m/z (Cl) 
384 ([M + H]+, 60%), 328 (66, [M + H - (RgOzCCnzl^) and 284 (53, [M + H - Boc]+).
(2S)-Prolyl-(2S)-isoleucyl-isobutylamide hydrochloride (72).
Me
Me
C
Me 
Me
HCl gas was bubbled Into ethyl acetate (50 cm^) at 0 °C for 1 h. Boc-(2S)-Pro- 
(2S)-Ile-NH-iBu (92) (1.0 g, 2.6 mmol) was added to the acidic solution and left 
for 1.5 h. at room temperature. The solvent was removed under reduced 
pressure to yield a white solid, which was recrystallised from m ethanol/ ethyl 
acetate (675 mg, 81%), m.p. 220 °C (decomp.) (lit.iso 220 °C); (Found: C, 56.3; H, 
9.25; N, 12.95. C15H 30N3O2CI requires C, 56.4; H, 9.45; N, 13.15%); m/z (Found: 
[M + H - HC1]+ 284.2338. C15H 30N 3Q2 requires 284.2338); [ a l p -66.1 (c 1 in 
MeOH); (Nujol)/ cm-i 3280 (NH str.), 1655 & 1637 (CO str. (amides)) and 
1538 (NH bend); 8^  (600 MHz, dg-DMSO) 0.85 (12H, m, lie & iBu CHg's), 1.10 
(IH, m, 1 X CH2 (lie)), 1.45 (IH, m, 1 x CH2 (lie)), 1.67 (IH, m, CH (iBu)), 1.74 
(2H, m, 1 X CH2 (Pro 3-H) & CH (He)), 1.84 (2H, m, CH2 (Pro 4-H)), 2.29 (IH, m, 
Ix C H ; (Pro 3-H)), 2.80 (IH, m, 1 x CH2 (iBu)), 2.95 (IH, m, 1 x CH; (iBu)) 3.15- 
3.3 (2H, m, CH; (Pro 5-H)), 4.18 (IH, d of d, /  7.80,8.50, a  CH (lie)), 4.23 (IH, d of
d, /  6.90, 8.10, a  CH (Pro)), 8.15 (IH, t, /  5.85, NH (iBu) and 8.65 (IH, d, /  8.50, 
NH  (lie)); 8(- (50.3 MHz, dg-DMSO) 11.0 (ÇH3 (lie C-5), 15.3 (CH3 (He C-3')),
20.0 (ÇH3 (iBu)), 23.6 (CH; (Pro C-4)), 24.4 (CH; (lie)), 28.0 (ÇH (iBu)), 29.9 (CH; 
(Pro C-3)), 36.8 (ÇH (lie)), 45.4 (CH; (Pro C-5)), 45.9 (CH; (iBu)), 57.8 (a  CH (lie)),
58.6 (a  CH (Pro)), 168.2 (CO (He)) and 170.8 (CO (Pro)); m/z (Cl) 284 ([M + H - 
HC1]+, 100%).
tag
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Boc-(2S)-phenylalanine-(2S)-isoleucine-isobutylami<ie (137).
AO
M e—4
Boc-(2S)-phenylalanine (5.30 g, 20 mmol) was dissolved in THF (80 cm^), N- 
methylmorpholine (2.18 cm^, 20 mmol) was added and the solution cooled to 
-15 °C. Isobutylchloroformate (2.72 cm^, 20 mmol) was added with stirring and 
the solution left for 5 min at -15 °C. Isoleudne-isobutylamide.HCl (92) (4.50 g, 
20 mmol) and N-methylmorpholine (2.18 cm®, 20 mmol) were dissolved in 
THF (~ 20 cm®) and added to the cold solution. The reaction was left at -15 °C 
for 5 min and a further 15 min at room temperature. The hydrochloride salts 
were filtered off and the THF removed under reduced pressure to yield a 
white solid (7.36 g, 85%). mp 167-169 °C; m/z (Found [M + H]+ 434.3019. 
C24H40N 3O4 requires 434.3019). (Nujol) /cm-i 3323 (NH), 1689 (Urethane 
CO), 1645 (Amide CDs), 1535 & 1510 (Amide II & Ar); 6^  (200 MHz, C^HClg) 
0.82-0.96 (12H, m, CHg's), 1.40 (9H, s, BOC), 1.0-2.0 (4H, m, CH(a), CH(b), 
CH2(c)), 2.87-3.20 (4H, m, CH;(a), CH2(b)), 4.26 (IH, t, /  6, Phe a-CH), 4.39 (IH, q,
7 8 , lie a-CH), 5.13 (IH, d, /  8, NH), 6.42 (IH, t, /  6, NHiBu), 6.71 (IH, d, /  8, 
NH) & 7.12-7.35 (5H, m, Ar); (50.3 MHz, C2HCI3) 11.27 (CH3 (a)), 15.49 ( 
CH3(b)), 20.04 (CH3(c)s), 24.48 (CH;(c)), 28.10 (BOC CH3S), 28.25 (CH(b)), 36.37 
(CH(a)), 37.69 (CH2(b)), 46.78 (CH2(a)), 55.89 (Phe a-CH), 58.12 (lie a-CH), 80.33 
(B0 C £(C H 3)3), 126.87 (Ar p-CH), 128.57 (Ar m-CH), 129.15 (Ar o-CH), 136.23 
(ArC- CH;), 155.48 (urethane CO) & 170.51 & 171.24 (amide COs); m/z (El) 434 
(M+, 23%), 378 (18, [M +2H - tBu]+), 360 (86, [M +2H - 0-tBu]+), 334 (35, [M +2H 
- BOC1+).
   •   " ~ - •• • • - ■ ■
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(2S)-PhenyIalanine-(2S)-isoleucme-isobutylamide hydrochloride (73).
This deprotection was carried out in an identical maimer to (92), using (137) 
(1.0 g, 2.3 mmol) in acidic ethyl acetate (50 cm®) to yield a white solid, which 
was recrystallised from m ethanol/ ethyl acetate (765 mg, 90 %). m.p. 142-
143 °C (decomp.); (Found: C, 61.20; H, 8.95; N, 11.27. C19H32N 3O2CI requires C, 
61.69; H, 8.72; N, 11.36%); m/z (Found: [M + H - HC1]+ 334.2495. 
requires 334.2494); [a]p-9.4 (c 1 in MeOH); (Nujol) /cm  ® 3303 (NH), 1653 
(COs), 1559 (Amide II) & 1502 (Ar); 5^ (600 MHz, d g-DMSO) 0.81-0.84 (12H, m, 
CHj's), 1.08 & 1.48 (2H, m, CH^lc)), 1.65-1.70 (2H, m, CH(a), CH(b)), 2.83 & 2.92 
(2H, m, CH2(a)), 2.97 (IH, ABX splitting, / ax  6, / ab 13.8, 1 of CH^ib)), 3.08 (IH, 
ABX splitting, / ax  6, / ab 13.8,1 of CH^fb)), 4.12 (IH, t, /  7.2 Hz, Phe a-CH), 4.16
(IH, app. t, /  8.4, He a-CH), 7.21-7.27 (5H, m, Ar), 8.08 (lH,-t, /  5.4, NHiBu), 8.21 
(3H, s, N H 3 + ) & 8.6 (IH, d, /  9, NH-Ile); 5c (50.3 MHz, dg-DMSO) 11.36 
(CH)(a)), 15.58 (CH,(b)), 20.49 (CH3(c)s), 24.71 (CHjfc)), 28.21 (CH(b)), 37.01 
(CHjfc)), 37.15 (CH(a)), 46.31 (CHzfa)), 53.25 (Phe a-CH), 57.56 (lie a-CH), 127.29 
(Ar p-CH), 128.69 (Ar m-CH), 129.89 (Ar o-CH), 135.04 (Ar C-CHg) & 167.79 &
170.46 (COs). m/z (Cl) 334 ([M + H - HC1]+, 100%), 316 (15, [M + 2H - HCl - 
NHg]+), 261 (6, [M + H - HCl - NHiBu]+), 187 (6 , [Ile-NHiBu+H]+), 86  (35, 
[H2NCHCH(CH3)Et]+), 74 (10, [iBu-NH3]+).
1
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D ipheny l [l-(N -benzyloxycarbonyl)-am ino]-2-phenylethy lphosphonate
( 7 4 ) .1 5 8 b
O
^  A
II .OPh 
OPh
Triphenyl phosphite (31.0 g, 0.1 mol), phenylacetaldehyde (18 g, 0.15 mol) and 
benzyl carbamate (15.1 g, 0.1 mol) were dissolved in glacial acetic acid (15 cm^) 
and stirred at room temperature until the exothermic reaction had ceased 
(about 1 h). The mixture was then heated to 80 °C for a further 1 h and the 
volatile products were then removed under reduced pressure on a boiling 
water bath. The yellow residue was dissolved in methanol (150 cm^) and left 
to crystallise at -10 for 3 h. After this time the crystalline product was 
collected by filtration, dissolved in the minimum quantity of hot chloroform 
and a 4 fold excess of methanol added to give the product as a white solid after 
storage overnight at -10 °C (14.Ig, 29%), m.p. 120-2 °C (lit.^^^^ 119-120 °C); m/z 
(Found: [M + H]+487.1549. CggH^^NOgP requires 487.1549); V^ax (Nujol) /cm -:
3287 (NH), 1720 (urethane CO), 1590 (amide II), 1262 (P=0) and 1212 (P-OPh); 
ÔH (300 MHz, C^HClg) 3.1-3.5 (2H, m, CH^-CH), 4.82 (IH, m, CH), 5.12 (2H, s, 
CH^-O), 5.34 (IH, d, /  10.5, NH) & 7.02-7.40 (20 H, m, aromatic); ôc (50.3 MHz, 
C^HClg) 36.5 (PhCH^CH), 49.8 ( d , / p _ H  158.1 PhCH^CH,), 67.7 (PhCH^-O), 120.8-
121.2 (aromatic C-4), 125.8-130.3 (aromatic C-2,3,5,6), 136.1 & 136.7 (quaternary 
aromatic) & 150.4 (urethane CO); ôp (121.5 MHz, C^HClg) 17.17 (88%) & 16.74 
(12%); m/2 (El) 487 (M +, 6 %), 394 (32, [M - OPh]+), 379 (15, [M - PhCH2 0 H]+), 
336 (100, [M -H 2NCO-OCH2PN+), 234 (13, [PO(OPh)2]+), 145 (37, [PhCH^CH- 
NHC01+), 94 (65, [PhOH]+) & 77 (15, Ph+).
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Dimethyl [l-(N-benzyIoxycarbonyl)-amino]-2-phenylethylphosphonate (75).^^^
A H OII .O M e
The diphenyl compound (74) (15.4 g, 31 mmol) was dissolved with warming 
in dry methanol (200 cm^) and sodium (3.12 g, 64 mmol) in dry methanol 
(30 cm^) added dropwise w ith stirring. The solution was stirred at room 
tem perature overnight, then the volume reduced to 20 cm^ on a rotary 
evaporator and ethyl acetate (200 cm^) added. The solution was washed with 
5 % sodium hydrogen carbonate solution (3 x 80 cm^), 0.1 M hydrochloric acid 
(1 X 80 cm^), water (1 x 80 cm^) and brine (1 x 80 cm^). The solution was dried 
(MgS0 4 ) and the solvent removed under reduced pressure to give a yellow 
oil. This was purified by flash chromatography on silica, eluting with ethyl 
acetate, to give the product as a white solid after trituration with petroleum 
ether (7.56 g, 67%), m.p. 67-69 °C (lit.^si 67-69 °C); m/z  (Found [M + H]+ 
364.1314. C^gH^gNOgP requires 364.1315); v^ax (Nujol) /cm -: 3224 (NH), 1710
(urethane CO), 1586 (amide II), 1258 (P=0) & 1057 (P-OMe); 5h (200 MHz, 
C^HClg) 2.84-3.3 (2H, m, PhCH^CH), 3.62 & 3.68 (6H, d, /  p_H 10.6, P(0)(0CHg)2), 
4.40 (IH, dt. /  7,8.6, PhCH^CH ), 4.97 (2H, s, PhCH^O), 5.81 (IH, d, /  7.1, -NH) &
7.20 (lOH, m, Ar); 5^ (50.3 MHz, C^HClg) 34.5 (PhCH^CH), 49.0 (d, PhCH^CH, /  
p.H 156), 52.8 (OMe), 65.5 (PhCH^O), 126.7-129.3 (aromatic), 137.4 & 137,7 
(quaternary aromatic) & 156.1 (urethane CO); Ôp (121.5 MHz, C^HClg) 26.83 
(91%) & 26.21 (9%); m/z  (Cl) 364 ([M + H]+, 100%), 259 (12, [M + 2 H -
1
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PhCH^Ol+X 230 (3, [M + H - PhCH^OCOl+X 120 (17, [PhCH2CHNH2l+), 108 (11, 
[PhCH20H]+) & 91 (13, [PhCH2]+).
M ethyl hydrogen [l-(N-benzyloxycarbonyl)-amino]-2-phenyl-ethyl- 
phosphonate (76).^5i
A H OII .OMe
The dimethyl compound (75) (3.63 g, 10 mmol) was dissolved in methanol 
(30 cm^) and 2 M sodium hydroxide solution (15 cm^) added with stirring. The 
solution was stirred at room tem perature for 12 h and then diluted with 
water (60 cm^) and washed with ethyl acetate (100 cm^). The aqueous layer was 
acidified to pH 2 with concentrated hydrochloric acid and extracted with ethyl 
acetate (3 x 70 cm^). The organic extracts were dried (MgSO^) and evaporated 
under reduced pressure to give the product as a white solid (2.69 g, 77%). m.p. 
126-127 °C (lit.151 126.5-127.5 °C). m/z (Found: [M + H]+ 350.1152. C17H 21NO5P 
requires 350.1154); v„,ax (Nujol) /cm -i 3289 (OH), 2665 & 2320 (P-OH), 1687 
(urethane CO), 1546 (amide II), 1219 (P=0), 1041 (P-OH) and 982 (PO-C); Ôh (200 
MHz, C % C l3) 2.93 (2H, m, PhCHzCH), 3.62 (3H, d, /ph  10.6, P(0 )0 CH3), 4.40 
(IH, dt, / n h  7.1,/c h  6.3, PhCH2CH ), 4.97 (2H, s, PhCH2 0 ), 5.64 (IH, br, OH), 
5.81 (IH, d, /  7.1, NH) and 7.15 (lOH, m, Ar); 5c (50.31 MHz, C^HClg) 38.55 
(PhCHzCH), 53.33 (d, /p c  103, PhCH2CH), 56.37 (d, /p c  21.1, OMe), 69.21 
(PhCH2 0 ), 126.71-129.36 (aromatic), 141.34 & 142.40 (quat. aromatic) and 156.17 
(urethane CO); ôp (121.5 MHz, C^HClg) 22.55 (9.5%) and 23.11 (90.5%); m/z (El)
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350 ([M + H]+ 5.4%), 320 (100, [M - OMe + 2H]+), 242 (18, [M - OMe - PhCHzO + 
2H]+) and 91 (49, PhCH2+).
M e th y l H y d ro g e n  [ l- (N -B e n z y lo x y c a rb o n y l) -a m in o ]-3 -m e th y l-  
butylphosphonate (78).
Ph^ NH OIIF^OMe
OH
To a stirred solution of benzyl carbamate (0.76 g, 5 mmol) and PCI3 (0.68 g, 
5 mmol) in acetyl chloride (10 cm^), was added dropwise isovaleraldehyde 
(0.52 g, 6 mmol, 1.2 eq) at 0 °C over a period of 10 minutes. The solution was 
then stirred at room tem perature for 1 h. After removal of the volatile 
compounds under reduced pressure, the resultant solid was suspended in dry 
THE (10 cm^) and an excess of dry methanol (10-20 mmol) was added slowly. 
The solution was then stirred at room temperature for 1.5 to 2 h. The solvent 
and volatile products were removed under reduced pressure to yield the 
product as a yellowy oil which was recrystallised from ether /  light petroleum 
(0.57 g, 36 %). m.p. 106-108 °C. m/z (Found: [M + H]+, 316.1314. C^^H^gNOgP 
requires 316.1314); (Nujol) /cm -: 328I (NH), 1689 (CO), 1543 (Amide 11), 
1270 (PC) & 1038 (P-OMe); 5^ (200 MHz, C^HCl^) 0.73-1.06 (6H, m, CH^s), 1.15- 
1.83 (3H, m, CH2, CH), 3.67 (3H, d, /  16, O-CH3), 4.0-4.25 (IH, m, a-CH), 5.08 
(2H, s, PhCH^O), 5.1 (IH, obscured, NH), 5.5 (IH, br, OH) & 7.28-7.45 (5H, m, 
Ar); ÔC (50.3 MHz, C^HClg) 21.8 & 24.1 (CH3), 25.04 & 25.31 (CH), 36.59 (CH^), 
44.91 & 48.16 (d, /p_H 164, a-CH), 53.3 (OMe), 67.8 (PhCH^O), 128.62-129.22 
(Aromatics), 137.12 (Quaternary aromatics) & 157.09 (Urethane CO), m/z (Cl)
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316 ([M + H]+, 77%), 298 (3, [M + H - OH]+), 225 (15, [M + H - Bz]+), 208 (8, [M + H 
- OBz]+).
(S)-Pipecolinic Acid (91).:7i
N H
(R/S)-pipecolinic acid (2.0 g, 15.5 mmol) was suspended in hot methanol 
(7 cm^) and (2S,3S)-tartaric acid (2.33 g, 15.5 mmol) was added with stirring. 
The solution was then cooled and allowed to crystallise. The crystals were 
filtered off and recrystallised from water and acetone to give (S)-pipecolinic- 
(2S,3S)-tartrate (m.p. 195-196 °C (lit.i7i 195-196 °C); [a]o = -19.7 (c 2 in HjO) 
(lit.:7i -21 (c 2 in H2O)). V^ax (Nujol)/ cm-: 3422 (NH) & 1713 (COs). Ôh (200 
MHz, ZHgO) 1.51-1.84 & 2.15-2.21 (6H, m, CH^'s (b), (c) & (d)), 2.97, 3.61 & 3.66 
(3H, m, a-CH & CH^(a)) & 4.61 (2H, s. Tartrate CH's); ôc (50.3 MHz, ^H^O)
24.31 & 24.57 (CHgS (b) & (c)), 29.07 (CHg (d)), 46.56 (CHg (a)), 61.06 (a-CH), 74.96 
(Tartrate CH's), 176.44 (Pip CO) & 177.86 (Tartrate COs). Pipecolinic tartrate 
was dissolved in water and then applied to a Amberlite IR-120 (H+) ion 
exchange resin (100 cm^ of resin). The column was washed w ith distilled 
water to remove the tartrate and then eluted with 10% aqueous ammonia 
solution to give the (S)-pipecolinic acid (0.57 g, 57 % yield), m.p. 268-270 °C 
(lit.:7: 270-272 °C); [a]^ = -23 ° (c 1.5 in H2O) (lit.:7: -26 (c 2 in H 2O)). V^^x 
(Nujol)/ cm-: 306O (NH) & 1647 (CO); Ôh (200 MHz, ^HgO) 1.65 (5H, m) & 2.10 
(IH, m) (CH2’s (b)-(d)), 2.85 (IH, m) & 3.37 (2H, m) (CH2(a) & a-CH); ôc (50.3 
MHz, ZHgO) 24.39 & 24.67 (CH^s (b) & (c)), 29.37 (CHg (d)), 46.48 (CHg (a)), 61.84
(a-CH) & 177.43 (Pip CO).
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Boc-(2S)-Pipecolinic acid (138).
b
OHa
(S)-Pipecolinic acid (91) (2.58 g, 20 mmol) was dissolved in 1 M NaOH (20 cm^) 
and t-butyl alcohol (20 cm^) added with stirring. Di-tert-butyl-dicarbonate 
(5.8 g, 26 mmol, 1.3 eq) dissolved in t-butyl alcohol (10 cm^) was then added, 
with any resulting precipitate dissolved with 1 M NaOH. The mixture was 
stirred at r.t. for 3 h and then the alcoholic layer was removed under reduced 
pressure. The aqueous layer was washed with light petroleum (30 cm^) and 
then acidified to pH 3 with 1 M sulphuric acid in an ice bath. The turbid 
mixture was extracted with diethyl ether (3 x 50 cm^ ) and the combined 
organic layers washed with distilled water (2 x 50 cm^). The organic layer was 
dried (MgSO^) and evaporated under reduced pressure to give a clear oil, 
which was recrystallised from e th e r/ light petroleum  to give a white 
crystalline solid (2.93 g, 64 %), m.p. 116-118 °C; (Found: C, 57.75; H, 8.15; N,
6.05. C^jH^gNO^ requires C, 57.65; H, 8.3; N, 6.1 %); m/z (Found: [M + H]+ 
230.139. C n H 2oN0 4  requires 230.1392); [ a ] o -27.3° (c 1 in MeOH); 
(N ujol)/ cm-i 3200-3000 (OH, br), 1747 (Acid CO), 1661 (Urethane CO), 1634, 
1349, 1317,1268,1257,1198, 1162,1144 & 1037; 5^ (200 MHz, C^HCls) 1.25-1.80
(5H, m) & 2.21-2.27 (IH, m) (CHz's (a), (b) & (c)), 1.46 (9h, s, Boc CHg's), 2.96 
(2H, t, /  7.5, CH2 (d)) & 3.97 (IH, m, a-CH); 8^ (50.3 MHz, C^HCls) 21.24 (CHz
(c)), 25.18 (CH2 (b)), 27.09 (CH2 (a)), 28.82 (Boc CH3S), 42.65 (CH2 (d)), 54.15 (a- 
CH), 80.80 (BocC(CH3)3), 156.07 (urethane CO) & 178.38 (acid CO); m/z (Cl) 247 
([M + N H 41+, 3%), 230 (10, [M + H]+), 174 (27, [M -tBu]+), 130 (100, [M + H - 
Boc]+).
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Boc-(S)-pipecolinic acid-(2S)-isoleucine-isobutylamide (139).
This compound was prepared in an identical manner to (135), except using 
(138) (4.12 g, 18 mmol) and (92) (3.34 g, 18 mmol) in dry THF (100 cm3); the 
crude white solid was recrystallised from ethyl acetate/ light petroleum  
(5.36 g, 75 %); v^ax (C^HOs)/ cm-i 2968 (NH), 1678 (COs), 1368 & 1162; 8^
(200 MHz, C^HCls) 0.90 (12H, m, CHgs), 1.12-2.23 (lOH, m, CH's (a) & (b), CHz's 
(b), (d), (e) & (f)), 1.47 (9H, s, Boc CHg's), 2.96-3.12 (4H, m, CHz's (a) & (c)>, 4.25 
(IH, app. t, Pip a-CH), 4.71 (IH, m. He a-CH), 6.29 (IH, br, i-Bu NH) & 6.72 (IH, 
br d, 1 8.9, lie NH); (50.3 MHz, C^HCls) 11.60 (CH3 (a)), 16.18 (CH3 (b)), 20.57
(CH3 (c)), 20.95 (CH2 (e)), 25.20 (CH2 (d)), 25.31 (CH2 (b)), 28.72 (CH2 (f)>, 28.90 
(Boc CH3S), 29.22 (CH (b)), 36.98 (CH (a)), 44.34 (CH2 (c)), 47.32 (CH2 (a)), 51.40 &
54.20 (a-CHs), 81.29 (C(CH3)3), 156.64 (urethane CO), 171.40 & 172.11 (amide 
COs).
■^1a
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(S)-Pipecolinic acid-(2S)-isoleucine-lsobutylamide hydrochloride (93).
c r
This compound was prepared in an identical manner to (92), using boc-(S)- 
pipecolinic acid-(2S)-isoleucine-isobutylamide (139) (1.98 g, 5 mmol); the 
crude off white solid was recrystallised from m ethanol/ acetone (1.5 g, 90 %), 
m.p. 140 °C (decomp.), m/z (Found: [M + H - HC1J+ 298.2495. C jgH jjN jO j
requires 298.2494). V^ax (Nujol)/ cm-i 3380, 3233 (NHs), 1670, 1632 (COs) & 
1546 (Amide II); 8^  (400 MHz, d s-DMSG) 0.81-0.85 (12 H, m, CHjs), 1.06-1.13 (1 
H, m, CH (b)), 1.42-1.50 & 1.62-1.75 (9 Hs, m, CH (a), CH^'s (b), (d), (e) & (f)), 
2.77-2.98 (3 H, m) & 3.16-3.19 (IH, m) (CH^'s (a) & (c)), 3.78-3.80 (1 H, m. He a-
CH), 4.17 (IH, t, /  8.2, Pip a-CH ), 8.11 (1 H, t, /  6, NHiBu), 8.57 (2 H, d, /  8.2, 
N H 2+) 69.2-9.4 (1 H, br. He NH); 8c (400 MHz, 4  - DMSO) 11.11 (CH3(a)), 15.46 
(CH3(b)), 20.17 (CH3(c)), 21.29 & 21.68 (CH^fe) & (f)), 24.45 (CH2(b)), 27.26 
(CH(b)), 28.03 (CH2(d)), 36.74 (CH(a)), 43.35 (CH2(b)), 46.05 (CH2(a)), 56.89 & 
57.37 (a-CHs), 168.37 & 170.41 (COs); m/z (Cl) 298 ([M + H - HC1]+, 83 %), 197 
(2, [M + H-HCl-CONHiBu]+), 84 (100, Piperidine ring).
n1m|- --- 1--
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(S)-Pipecolininic acid methyl ester hydrochloride (140).
N. H
(S)-Pipecolinic acid (91) (2.58 g, 20 mmol) was dissolved in freshly distilled 
methanol (80 cm^). Distilled thionyl chloride (3.19 cm^, 44 mmol, 2.2 eq) was 
added dropwise with stirring at 0 °C, the solution allowed to warm to room 
temperature and then refluxed gently for 90 min. The solvent was removed 
under reduced pressure to yield a white solid which was recrystallised from 
m ethanol/ diethyl ether (2.19 g, 61 %); 0^ (200 MHz, C ^ Œ H )  1.64-1.93 (5H,
m) & 2.26-2.32 (IH, m) (CH2 (b), (c) & (d)), 3.11 & 3.39 (2H, m, CH2 (a)), 3.86 (3H, 
s, OCH3) & 4.08 (IH, ABX, /  AX 3.64, /ab 11.25, a-CH); 8^ (50.3 MHz, C^HaO^H)
23.04 & 23.13 (CH2 (b) & (c)), 27.42 (CH2 (d)), 45.50 (CH2(a)), 54.04 (OCH3), 58.15 
(a-CH) & 170.64 (CO).
D iphenyl l-(N-benzyloxycarbonyl)-amino-methane phosphonate (141).^59
O
Ph" ^NH\ IIH -y— P^OPh 
H OPh
A mixture of benzyl carbamate (5.03 g, 33 mmol), paraform aldehyde (1 g, 
33 mmol), acetic anhydride (8 cm^) and glacial acetic acid (5 cm^) was stirred 
for 3 h at 60-70 °C. Triphenyl phosphite (10.33 g, 33 mmol) was then added 
and the mixture stirred for a further 2 h at 110-120 °C. After removal of the 
acetic acid and acetic anhydride under reduced pressure, the mixture was
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dissolved in m ethanol and allowed to stand at -10 °C overn igh t The 
precipitate formed was collected by filtration and washed with methanol. 
This was then recrystallised from chloroform/ methanol to give a white solid 
(2.70 g, 20%), m.p. 113-114 °C (lit.:59 114-116 °C). m/z  (Found: [M + H]+ 
398.1155. C21H21NO5P requires 398.1152); v^ax (Nujol) /cm -i 3273 (NH), 1721 
(urethane CO), 1594 (aromatic), 1558 (amide II), 1226 (P=0), 953 (P-OPh) and 
766 (aromatic); Ôh (200 MHz, C^HClg) 3.98 (2H, d, /  6.2, CH2PO), 5.13 (2H, s, 
CHz-Ar), 5.32 (IH, br s, NH) and 7.08-7.41 (15H, m, aromatic); ôc (50.3 MHz, 
C^HCla) 35.97 and 39.15 (d, /pc 160, CHg-PO), 67.91 (CHg-Ar), 120.9-130.3 
(aromatic) and 163.1 (urethane CO); ôp (121.49 MHz, C^HCl^) 15.82 (96.2 %) 
and 15.24 (3.8 %).; m/z (Cl) 415 ([M + NH41+, 2 %), 290 (100, [OCNCH2PO(OPh)2 
+ H]+), 264 (7, [M + H - Cbz]+), 94 (16, PhOH) & 91 (33, PhCH2+).
l-DiphenylmethyI-amino-3-methyl-butane phosphonous acid (142)J^i
Ph
NH
P-OH
Me.
Me
To a refluxing solution of aminodiphenylmethane (1.84 g, 10 mmol), aqueous 
hypophosphonous acid (50 %, 1.72 g, 10 mmol) and 1 M hydrochloric acid (10 
cm^, 1 eq) in w ater (20  cm^), was added dropw ise w ith  stirring, 
isovaleraldehyde (0.86 g, 10 mmol) in water (10 cm^). Heating was continued 
for 2 h  during which time a white solid precipitated out. The solution was 
cooled, then the solid collected by filtration and washed with acetone (2.50 g, 
79 %), m.p, 215-217 °C (lit.i^i 215-218 °C). 0» (200 MHz, ^HzO), 0.4-0.6 (6H, m, 
CHg's), 1.2-1.6 (3H, m, CH & CH2 on alkyl chain), 2.3 (IH, m, a-C H ), 4.9 (IH, s, 
Ph2CHN), 6.7-7.1 (lOH, m, aromatics), 5.5 & 8.0 (IH, d, /  500, P(O)-H).
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1-Amino 3-methyl butane phosphonous acid (143).^^^
Ps-OH
The diphenylm ethylam inom ethyl butane phosphonous acid (142) (2.50 g, 
8 mmol) was heated together with an excess of hydrobromic acid (48%, 6.75 g, 
40 mmol, 5 eq) at 100 °C for 2-3 h until 2 distinct phases could be observed. 
The mixture was then evaporated to dryness under reduced pressure and the 
residue taken up in water. The aqueous solution was then washed with ether 
(3 X 30 cm^) to remove the diphenylmethyl bromide and then evaporated to 
dryness. The oily residue was dissolved in ethanol (25 cm^) and propylene 
oxide added until precipitation was observed. The mixture was then allowed 
to stand until complete precipitation had occurred. The solid was filtered off, 
washed in turn with ethanol and ether and then dried to give a white solid 
(0.43 g, 35 %), m.p. 222-224 °C (lit.i6i 222-223 °C). Ôh (200 MHz, ^HzO) 0.8-0.9 
(6H, m, CHs's), 1.5-1.7 (3H, m, CHz & CH), 3.12 (IH, m, a-CH), 5.6 & 8.2 (IH, d, /  
520, P(O)-H). ÔC (50.31 MHz, ^HgO) 23.3 & 24.7 (CHg's), 26.6 (CH), 37.6 (CHj), &
50.4&52.2 (a-CH ,/PC91).
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l-Amino-2-phenyl-ethyl phosphonous acid (100).^^^
This was prepared as for (143), except using l-(diphenylm ethyl)-am ino-2- 
pheny 1-ethyl phosphonous acid (99) (4.14 g, 11.8 mmol), yielding the product 
as a white solid (1.81 g, 83 %), m.p. 226-228 (lit.i6i 227-228 °C); 5^ (200 MHz,
2H2O) 2.82 (IH, m, 1 of benzyl CH2), 3.31 (2H, m, 1 of benzyl CH2 & a-CH), 6.99 
(IH, d, /  536.7 Hz, PH) & 7.25-7.40 (5H, m, aromatic CHs); 6^ (50.3 MHz, ^HiO)
34.72 (benzyl CH2), 54.77 (d, /  88 Hz, a-CH), 130.39-132.20 (aromatic CHs) & 
137.87 (quaternary aromatic); ôp (121.5 Hz, 2H2O) 18.94 (100 %).
l-Benzyloxycarbonyl-amino-2-phenyl-ethyl phosphonous acid (lOl).i^^
O
NH OPh
P“ OH
l-A m ino-2-phenyl-ethyl phosphonous acid (100) (555 mg, 3 mmol) was 
dissolved in water (10 cm^) and the pH of the resultant solution adjusted to
9.5 with 5 M NaOH. Benzyl chloroformate (665 mg, 555pl, 3.9 mmol, 1.3 eq) 
was added slowly and the solution stirred at r.t. for 4 h. During this time, the 
pH was periodically checked and restored to 9-9.5 via the addition of 5 M 
NaOH solution. The aqueous solution was washed w ith diethyl ether
!
j
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(10 cm^) and then slowly added to a 2:3 mixture of 6 M HCl and ice. The 
resulting precipitate was collected by filtration and recrystallised from ethyl 
acetate/ light petroleum (813 mg, 85 %); 5^ (200 MHz, C^HaO^H) 2.82 & 3,15
(2H, m, benzyl CH2), 3.99-4.12 (IH, m, a-CH), 4.87-5.06 (2H, m, Cbz CH2), 6.99 
(IH, d, /  553.5 Hz, PH) & 7.13-7.29 (lOH, m, aromatic CH's); 0^ (50.3 MHz,
C^HaO^H) 34.03 (benzyl CH2), 53.83 (d, /  108, a-CH), 67.92 (Cbz CH2), 128.06- 
130.55 (aromatic CH's), 138.41 & 138.61 (quaternary aromatics) & 157.25 
(urethane CO).
Boc-(2S)-Asparagine-methyl ester (144).
O
O
M eM^e
A solution of boc-(2S)-asparagine (0.42 g, 1.8 mmol) in dichloromethane 
(7 cm^) was cooled to 0 °C and diazomethane added dropwise with stirring 
until the yellow colour remains. The mixture was then allowed to stir at 
room tem perature for 2 h. The excess diazomethane was flushed from the 
flask using nitrogen, and the solvent removed under reduced pressure to 
yield a yellowy oil. Careful recrystallisation from ethyl aceta te / light 
petroleum yielded a white solid (375 mg, 85 %), na.p. 85-87 °C. m/z (Found: 
[M + H]+ 247.1294. CJ0H 19N 2O5 requires 247.1294). v^ax (Nujol) / cm~^ : 3406,
3353 (NHs), 1742 (Ester CO), 1703 (Urethane CO), 1657 & 1626 (Amide I and II) 
& 1525 (Urethane Amide II); Sy (200 MHz, C^HClg) 1.4 (9H, s, Boc CHg's), 2.7 
(IH, ABX splitting,, 1 of CHg), 2.9 (IH, ABX splitüng, /ax  4, /ab 16.3,1 of CH2), 
3.7 (3H, s, OMe), 4.5 (IH, m, a-CH), 5.75 (IH, d, NH, /  8.2) & 6.0 (2H, s, NH^).
NH
OCH:
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ôc (50.3 MHz, C2HCI3) 28.8 (Boc CH^'s), 37.9 (CH;), 50.9 (a-CH), 53.1 (OCH3),
80.6 (Boc ClCHg);) & 172.4,172.6, 173.0 (3 COs). m/z (Cl) 247 ([M + H]+,40%), 
191 (58, [M + H - tBu]+), 176 (6, [M + H - G-tBu]+), 147 (100, [M + H - Boc]+).
Diphenyl l-[N-Benzyloxycarbonyl]-amino-3-methyl-butyl phosphonate
(145).158b
AP h " ^ 0  NH O
-Rc-OPhH
Me
Me
Y
OPh
This compound was prepared in a manner identical with that for (74) except 
using iso-valeraldehyde (12.9 g, 100 mmol) in 55 % yield, m.p. 123-125 °C 
(lit.tS8b 122-123 °C). m/z (Found: [M + H]+ 454.1783. CjsHj^NOgP requires 
454.1783); (Nujol) /cm-i 3270 (NH), 1713 (CO), 1591 (Ar C-C), 1550 (Amide 
II), 1270 (P=0), 1230 (P-OPh) & 946 (Pv-OPh); 5h (200 MHz, C^HClg) 0.84-0.98 
(6H, m, CHg's), 1.70-1.92 (3H, m, CH & CH;), 4.59 (IH, m, a-CH), 5.12 (2H, s, 
CH ;0), 5.34 (IH, d, /  10.4, NH) & 7.01-7.33 (15H, m, aromatics). Sc (50.3 MHz, 
C^HClg) 21.62 & 23.81 (CHg's), 24.77 & 25.05 (CH), 39.03 (CH;), 45.81 & 48.95 (d, /  
P_H 158.3, a-CH), 67.79 (Ph£H ;0), 120.85-130.29 (aromatics), 137.2 (Quaternary 
aromatic) & 158.42 (urethane CO), m/z (Cl) 454 ([M + H]+, 100%), 360 (8, [M + 
H - OPh]+), 346 (7, [M + H - OBz]+), 252 (2, [M + H - OPh - OBz]+).
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Diethyl [l-(benzyloxycarbonyl)-amino]-2-phenyl-ethyl phosphonate (146).
°  ip \  ^^OCHgCHa 
'"OCHgCHg
This compound was prepared in a manner identical to that used for (75), 
except using dry ethanol (150 cm^) and to it was added sodium  (1.52 g, 
66 mmol) in d ry  ethanol (40 cm^). A fter w ork-up  and colum n 
chromatography (eluting with ethyl acetate), the product was isolated as a 
clear oil which could be further purified by recrystallisation using ether/ light 
petroleum  (8.7 g, 74%), m.p. 64-66 °C; m/z (Found: [M + H]+ 392.1627. 
C20H 27NO5P requires 392.16267); v^ax (Nujol) /cm-: 3233 (nH), 1722 (CO), 1548 
(Amide II) & 1221 (PC); 0^ (200 MHz, C^HCls) 1.26 (6H, t, /  7, OCH2G & 's), 2.87
& 3.24 (2H, m, benzyl CH2), 4.08 (4H, q, /  7, OCH^CHs’s), 4.38 (IH, ddd, /  4.5, 
10.5,15.9, a-CH), 5.00 (2H, s, Cbz CH2), 5.19 (IH, d, /10.5, NH) & 7.10-7.32 (lOH, 
m, aromatic CHs); 6^ (50.3 MHz, C^HCla) 16.92 (OCH2C% 's), 36.45 (benzyl
CH2), 49.09 (d, /  157, a-CH), 63.08 (OCH^CHs's), 67.40 (Cbz CH2), 127.27-129.73 
(aromatic CHs), 137.20 (quaternary aromatic) & 156.15 (urethane CO); Ôp 
(121.5 MHz, C^HCls) 24.36 (90 %) & 23.77 (10 %); m/z (Cl) 392 (100 %, [M + 
H]+), 301 (3, [M + H - PhCH2]+), 284 (31, [M + H - PhCH20H]+).
   • - ■  1: ' '
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Ethyl hydrogen [l-(benzyIoxycarbonyl)-amino]-2-phenyl-ethyl phosphonate
(96).
Ph'
This compound was prepared in a manner identical to that used for (76), 
except using  d iethy l l-(N -benzyloxycarbonyl)-am ino-2-phenyl ethyl 
phosphonate (146) (3.91 g, 10 mmol) in ethanol (50 cm^). The product was 
recrystallised from dichloromethane/  light petroleum to yield a white solid 
(1.78 g, 49 %), m.p. 127-128 °C; m/z (Found: [M + H]+ 364.1314. C igH isN O s? 
requires 364.13137); (Nujol) /cm -: 3285 (NH), 1688 (CO), 1539 (Amide II) & 
1214 (PC); 5h (200 MHz, C^HCls) 1.27 (3H, t, ] 7, OCHzÇI^), 2.84 & 3.23 (2H, m, 
benzyl CH2), 4.13 (2H, q, /  7, OCH2CH3), 4.43 (IH, m, a-CH), 4.91-5.06 (2H, m, 
Cbz CH2), 5.45 (IH , d, /  10, NH) & 7.17-7.31 (lOH, m, aromatic CH's); 5c
(50.3 MHz, C^HCb) 16.83 (OCHoCHi). 36.19 (benzyl CH2), 49.34 (d, /158.5 a-CH),
63.32 (OCH2CH3), 67.43 (Cbz CH2), 127.26-129.69 (aromatic CHs), 136.78 & 137.17 
(quaternary aroma tics) & 156.53 (urethane CO); 5p (121.5 MHz, C^HCla) 25.93 
(80 %), 25.23 (20 %); m/z (Cl) 364 ([M + H]+, 18%), 273 (91, [M + H - PhCH2l+), 
256 (49, [M + H - PhCH20H]+), 108 (100, PhCH20H).
■4
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Cbz-(R/S)-Phe-[PO(OEt)-NH]-(2S)-Phe-(2S)-Ile-NH-iBu(94).
P h - ^ O ^ N H  o ,  O E t /
H 2  A  H M i 'r MeoMe b
H'/vV F\ J .  .N.
N Me
To e thy l hyd rogen  l-(N -benzy loxycarbony l)-am ino-2 -pheny l-e thy l 
phosphonate (96) (545 mg, 1.5 mmol) in dry dichloromethane (15 cm^) was 
added thionyl chloride (357 mg, 219 |Lil, 3 mmol, 2 eq) dropwise with stirring at 
0 °C. The flask was flushed with nitrogen to remove the acidic gases formed 
during the reaction. The solution was then allowed to stir at r.t. for 4 h, with 
periodic flushing during that time. The solvent was removed under reduced 
pressure, the residue taken up in more dry dichloromethane (15 cm^) and 
flushed again. The solvent was again removed, more dichloromethane was 
added and the flask was flushed with nitrogen. The solution was cooled to
0 °C in an ice-bath and (2S)-Phe-(2S)-Ile-NHiBu.HCl (73) (554 mg, 1.5 mmol) 
and triethylamine (379 mg, 522 pi, 3.75 mmol, 2.5 eq) in dry dichloromethane 
(10 cm^) was added dropwise with stirring. The solution was allowed to 
warm to r.t. and stirred overnight. The organic solution was washed with
1 M HCl (2 X 10 cm^), 5 % sodium bicarbonate solution (10 cm^) and saturated 
brine (10 cm^). The organic layer was dried (MgSO^), filtered and evaporated 
to yield a clear oil which resisted crystallisation (397 mg, 39 %); (Found: C, 
65.3; H, 7.75; N, 8.05. C37H 51N 4O6P requires C, 65.45; H, 7.6; N, 8.25 %); m/z 
(Found: [M + H]+ 679.3623. C37H52N 4O6P requires 679.3624); (Nujol) /cm -: 
3331 (NH), 1729 (urethane CO), 1699 & 1675 (amide CO's) & 1265 (PC); 8^
(200 MHz, C^HCls) 0.82-0.93 (12H, m. He & iBu CH3S), 0.98-1.52 (3H, m. He CH
■ - ■   ' ' ' '■■ .
:
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& CH2), 1.18-1.33 (3H, m, OCH2CH3), 1.68-1.87 (IH, m, IBu CH), 2.70-3.32 (6H, 
m, benzyl CHzS & IBu CH2), 3.63-3.77 (2H, m, Phe & He a-CHs), 4.11 (2H, q, /
7.6, OCH2CH3), 4.31-4.55 (IH, m, CH-F), 5.02 (2H, s, Cbz CH2), 7.09-7.42 (15H, m, 
aromatic CHs); 0^ (75 MHz, C^HClg) 10.89 (CH3 (a)), 15.22 (CH3 (b)), 16.83
(P0 (0 CH2£H 3)), 18.92 (CH3 (c)), 24.11 (He CH2), 27.56 (z-Bu CH), 36.64 & 36.79 
(A1C H 2CH* & He CH), 39.28 (Phe CH2), 45.0 (i-Bu CH2), 48.9-51.7 (CH’^ & 
PO(OCH2CH3)) 55.37 & 56.82 (a-CH’s), 64.51 (Cbz CH2), 125.62-129.41 (aromatic 
CH's), 137.61-138.10 (quaternary aromatics), 154.96 (urethane CO) and 170.41 & 
172.10 (amide CO's); ôp (121.5 MHz, C2HCI3) 29.52, 29.74, 29.89, 29.99; m/z 
(FAB) 701 ([M + Na]+, 22 %)., 679 (72, [M + H]+)
Dipropyl [l-(benzyIoxycarbonyl)-ammo]-2-phenyI-ethyl phosphonate (147).
Ph
To dry n-propanol (70 cm^), was added sodium hydride (40 % dispersion in 
oil, 1.32 g, 22 mmol, 2.2 eq). Once the solution was homogeneous, diphenyl 1- 
(N -benzyloxycarbonyl)-am ino-2-phenyl-ethyl phosphonate (74) (4.87 g, 
10 mmol) was added in one portion with stirring at r.t. The solution was 
allowed to stir overnight, then the volume reduced to 20 cm^ on a rotary 
evaporator and ethyl acetate (70 cm^) added. The solution was washed with 
5 % sodium hydrogen carbonate solution (3 x 30 cm^), 0.1 M hydrochloric acid 
(30 cm^), water (30 cm^) and brine (30 cm^). The solution was dried (MgS04), 
filtered and the solvent removed under reduced pressure to give a yellow oil. 
This was purified by column chrom atography (1:1 ethyl acetate:light
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petroleum) to give a white solid which was recrystallised from e ther/ light 
petroleum  (2.30 g, 55% ), m.p. 55-57 °C; m/z (Found: [M + H]+ 420.1940. 
CjzHjiNOsP requires 420.19397); (Nujol) /cm-: 3205 (NH), 1711 (CO), 1557 
(Amide II), 1268 & 1215 (PC); 8 ^  (200 MHz, C^HCb) 0.93 (6H, t, /  7.7,
(XHzCHzCTb's), 1.52-1.75 (4H, m, 0 CH2O ^ C H 3's), 2.78-2.95 & 3.17-3.31 (2H, 
m, benzyl CHz), 4.01 (4H, q, /  6.6, OCHiCmCHi's). 4.42 (IH, ddd, /  4.4,10.3, 26.7, 
a-CH), 5.00 (2H, s, Cbz CH;), 5.13 (IH, d, /  10.3, NH) & 7.11-7.29 (lOH, m, 
arom atic CH's); 8 c (50.3 MHz, C^HCb) 10.48 (OCH^CHiC H /s). 24.37
(OCH2Qjb<3 l3’s), 36.57 (benzyl CH2), 49.13 (d, Jqp 156.8, a-CH), 67.38 (Cbz CH2), 
68.51 (OCH2CH2CH3 S ) ,  127.25-129.72 (aromatic CH's), 136.67 & 136.87 
(quaternary aromatic) & 156.12 (urethane CO); 8p (121.5 MHz, C^HCls) 24.57 
(11 %), 24.32 (81 %), 23.71 (8 %); m/z (El) 419 (M+, 1%), 312 (1, [M - OCH2PW+), 
91 (100, PhCH2+), 43 (73, CH2CH2CH3+).
Propyl hydrogen [l-(benzyloxycarbonyl)-aminol-2-phenyl-ethyl phosphonate
(97).
Ph'
This com pound was prepared in a manner identical to that used for (76), 
except using  d i-n-propyl l-(benzyloxycarbonyl)-am ino-2-phenyl-ethyl 
phosphonate (147) (2.10 g, 5 mmol), n-propanol (15 cm^) and 2 M sodium  
hydroxide (10 cm^). The resu lting  solid was recrysta llised  from  
dichlorom ethane/ light petroleum  to yield the product as a white solid 
(338 mg, 18 %), m.p. 120-122 °C; m/z (Found: [M + H]+ 378.1470. C19H 25N O 5P
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requires 378.1470); (Nujol) /cm-i 3290 (NH), 1719 (CO), 1540 (Amide II) & 
1252 (PC); 5h (200 MHz, C^HCIs) 0.90 (3H, t, J 7.3, OCHoCHoCH^). 1.64 (2H, tq, /
6 .6, 7.3, OCH9CH2CHO. 2.83 & 3.25 (2H, m, benzyl CH2 ), 4.01 (2H, q, /  6.6, 
OCHiCHiCHx). 4.32-4.45 (IH, m, a-CH), 4.91-5.05 (2H, m, Cbz CH2), 5.37 (IH, d, 
/  10.4, NH), 7.04-7.45 (lOH, m, aromatic CH's); 5c (50.3 MHz, C^HCls) 10.46
(OCHiCHoCHs). 24.25 (OCH2a fcC H 3), 36.24 (benzyl CH2), 49.41 (d, /cp 158, a- 
CH), 67.42 (Cbz CH2), 68.42 (OÇH2CH2CH3), 127.22-129.65 (aromatic CH's),
137.20 (quaternary aromatic), 156.45 (urethane CO); 6p (121.5 MHz, C^HClg) 
25.86 (76 %), 25.06 (24 %); m/z (Cl) 378 ([M + H]+, 41%), 287 (52, [M + H - 
PhCH2l+), 270 (26, [M + H - PhCH2 0 H]+), 108 (100, PhCH20H+), 91 (83, PhCH2+).
4,4-Di-hydroxymethyl oxazolidinone (107).
1
HO OH
Tris (hydroxymethyl) aminomethane (60.5 g, 0.5 mol), anhydrous potassium 
carbonate (7.0 g, 0.05 mol) and diethyl carbonate (64.9 g, 66.6 cm^, 0.55 mol) 
were heated together at 135 °C under nitrogen and stirred using a mechanical 
stirrer. This was stirred until all had dissolved and with the receiver flask 
cooled in ice, ethanol was collected over several hours until approx. 57  cm^ 
had collected. At this point, the oil bath was removed and the thick glutinous i
mass dissolved as far as possible in methanol. The remaining solid (mostly 
potassium  carbonate) was rem oved by filtration and the filtrate was 
evaporated under reduced pressure to yield 93 g of crude product, which was 
recrystallised from methanol (55.93 g, 76 %), m.p. 105-107 °C; (Found: C, 41.1;
H, 6.3; N, 9.5. C5H9NO4 requires C, 40.85; H, 6 .2; N, 9.5 %); m/z (Found: [M +
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NH41+ 165.0875. CgHj3N 204  requires 165.0875); (Nujol) / cm-^ 3600-3000 
(br, OH), 3357, 3235 (NH), 1742,1733 (CO), 1423,1378, 1281, 1183, 1137 & 1055; 
5h (200 MHz, de-DMSO) 3.37 (4H, s, CHzOHs) & 4.07 (2H, s, ring CHz); 6^ (50.3
MHz, (ig-DMSO) 62.49 (Quaternary carbon), 63.34 (CHiOHs), 68.30 (ring CH2) & 
158.99 (Urethane CO); m/z (Cl) 165 ([M + N H 4]+, 83%), 148 (100, [M + H]+) & 
122 (23, [Tris + H]+).
4, 4-(N,N,N’,N-Tetramethyl)-di-hydrazone oxazolidinone (115).
HN
/
To a stirred solution of oxalyl chloride (5.59 g, 3.78 cm^, 44 mmol) in 
dichlorom ethane (40 cm^) at -40 to -50 °C was slowly added dim ethyl 
sulphoxide (20 cm^) in dichloromethane (10 cm^). After 3 min, the diol (107) 
(2.94 g, 20 mmol) was added in a mixture of dimethyl sulphoxide (20 cm^) and 
dichlorom ethane (10 cm^). After stirring the reaction mixture for about 
15 min, triethylamine (8.08 g, 11.1 cm^, 80 mmol) was added and the reaction 
mixture stirred for an additional 15 min before being allowed to warm to r.t. 
1,1-Dimethyl hydrazine (9.6 g, 12.2 cm^, 160 mmol) and magnesium sulphate 
(9.6 g, 80 mmol) were added with stirring and the reaction mixture allowed to 
stir at r.t. for 2-3 h. Water (40 cm^) was added and the organic layer separated, 
washed with saturated brine, dried (MgS0 4 ) and filtered. Removal of the 
solvent under reduced pressure yielded an orange-yellow oil which was 
purified by column chromatography on silica, eluting with ethyl acetatedight 
petroleum (7:3) (2.15 g, 47%), b.p. 120-130 °C/10 mm Hg; (Found: C, 47.3; H,
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7.95; N, 31.05. C9H 17N 5O2 requires C, 47.55; H, 7.55; N, 30.85%); m/z (Found: [M 
+ H]+, 228.1461. C9HJ8N5O2 requires 228.1460); v^ax (neat)/ cm 1 3271 (NH), 
1754 (C=N), -1700 (obscured, C=0), 1589,1268,1189,1138 & 1038; (200 MHz,
C^HCls) 2.80 (12H, s, N-CH3S), 4.56 (2H, s, CH2), 5.95 (IH, br, NH) & 6.49 (2H, s, 
hydrazone CHs); 8ç. (50.3 MHz, C^HCls) 43.17 (N-CH3S), 63.38 (Quaternary C),
72.56 (CH2 ), 132.52 (hydrazone C =N ) & 159.73 (urethane C=0); m/z (Cl) 228 
([M + H]+, 17%), 200 (13, [M + H - C01+) & 89 (100, [M + H - CO - NN(CH3)2 -- 
N(CH3)2 +5H]+).
Tris-hydroxymethyl-hydroxymethane (148).
OH
OH OH
Tris-hydroxymethyl-aminomethane (0.61 g, 5 mmol) was dissolved in 1 M 
HCl (20 cm^) and cooled to 0 °C. To this was added sodium nitrite (450 mg,
6.5 mmol, 1.3 eq) portion wise and with stirring. This was allowed to warm to 
r.t. and stirred until no further gas was evolved. The reaction was then 
quenched by the addition 2 M NaOH (20 cm^). The solvent was removed 
under reduced pressure, acetone (20 cm^) was added and the solution 
decanted. The solvent was removed under reduced pressure to yield a white 
solid (281 mg, 46 %); m/z (Found: [M + N H 4 - H 2 01+ 122.082. C4H 12NO3 
requires 122.0817); (Nujol) /cm -: 2350-3300 (br, OH's), 1652, 1634, 1557, 
1553 & 1297; 8^  (200 MHz, 2H2O) 3.78 (6H, s, CH2's); 8^ (50,3 MHz, 2H2O) 62.40
(CH2 's) & 64.51 (quaternary C); m/z (Cl) 12 2  ([M + N H 4 - H 2 0 ]+), 100%, 104 (3, 
[M - H201+), &90 (7, C0(CH 20H)2+).
” 3 j
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3-[(Benzyloxycarbonyl)-amino]-benzaldehyde (105).
Stannous chloride dihydrate (6.77 g, 30 mmol) was dissolved in concentrated 
hydrochloric acid (9 cm^) and cooled in an ice bath. To this was added 3- 
nitrobenzaldehyde (1.51 g, 10 mmol) in one portion and the mixture was 
stirred vigorously until the solid had dissolved, leaving a clear red solution. 
Recooling the solution in ice to 2 °C resulted in the formation of an orange- 
red paste which was filtered through a sintered glass filter funnel and used 
immediately. The orange-red solid was dissolved in 2 M sodium hydroxide 
solution (10 cm^) and cooled in an ice bath. Benzyl chloroformate (2.22 g, 1.85 
cm^, 13 mmol) was added in 6 portions over 25 min and the solution was 
then stirred at r.t. overnight. The pH was maintained above 7 by the periodic 
addition of sodium hydroxide solution. On completion of the reaction (by 
t.l.c.), the solution was acidified and extracted with dichloromethane (3 x 20 
cm^). The combined organic extracts were dried (MgSO^), concentrated under 
reduced pressure and then purified by column chrom atography on silica, 
eluting w ith ethyl acetateilight petroleum (3:2) to give a white solid (1.3 g, 
51%), m.p. 102-104 °C; (Found: C, 70.7; H, 5.15; N, 5.35. C15H 13NO3 requires C, 
70.6; H, 5.15; N, 5.5 %); m/z (Found: [M + H]+ 256.0978. C15H 14N O 3 requires 
256.0974); v i^ax (Nujol) /cm -: 3268 (NH), 1729 (Aldehyde), 1700 (Urethane), 
1683, 1594, 1558 (Amide II and aromatics), 1326, 1294, 1271, 1227, 1169, 1154 & 
1047; (200 MHz, C2HCI3) 5.21 (2H, s, benzyl CHj), 7.25-7.94 (9H, m, aromatic
CH's) & 9.95 (IH, s, aldehyde CH); 6^ (50.3 MHz, C2HCI3) 68.20 (benzyl CHg),
 ' I- ' i i:.-. - -  - ' . '
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120.29, 125.35, 125.60, 129.27, 129.40, 129.58 & 130.69 (aromatic CHs), 136.69,
138.00 & 139.81 (quaternary aromatics), 154.29 (urethane CO) & 193.15 
(aldehyde CO); m/z (Cl) 256 ([M + H]+, 57%) & 91 (100, PhCH2+).
3 ,3'-[(BenzyloxycarbonyI)-amino]-benzoin (103).
O OH
1
-V
To 3-ethyl-5-(2-hydroxyethyl)-4-m ethyl-th iazolium  brom ide (26 m g, 
0.1 mmol) in dry ethanol (10 cm^) under nitrogen was added triethylamine 
(60 mg, 84 pi, 0.6 mmol). To this solution was added 3-(N-benzyloxycarbonyl)- 
aminobenzaldehyde (105) (510 mg, 2 mmol) and the mixture refluxed for 40 h. 
The m ixture was allowed to cool and the solvent was rem oved under 
red uced  p ressure . The crude p roduct was pu rified  by colum n 
chromatography on silica, eluting with ethyl acetate/ light petroleum  (2:3) 
(130 mg, 25 %), m.p. 50 °C (decomp.); (Found: C, 70.2; H, 5.05; N, 5.4. 
C30H 26N 2O6 requires C, 70.55; H, 5.15; N, 5.5 %); (Nujol) /cm -: 3500-3200 
(br, OH), 3311 (NH), 1730 (ketone CO), 1701 (urethane CO), 1595, 1546 & 1491 
(Amide II and Aromatics), 1309,1219 & 1065; 0^ (200 MHz, C2HCI3) 4.69 (IH, s,
OH), 5.09-5.16 (4H, m, benzyl CH2*s), 5.86 (IH, s, CH), 6.96-7.96 (18H, m, 
aromatic CH's); 6^ (50.3 MHz, C^HClg) 67.64 & 67.70 (benzyl CH2 's), 76.86 
(CH(OH)), 112.80-130.25 (aromatic CH's), 134.07-140.06 (quaternary aromatics), 
153.98 & 154.24 (urethane CO's) & 198.51 (ketone CO); m/z (Cl) 511 ([M + H]+, 
11%).
i
-  •
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N, N '-Dibenzylmalonamide (149).
O O
To diethyl malonate (800 mg, 5 mmol) in dry ethanol (10 cm^) was added 
benzylamine (1.07 g, 1.09 cm^, 10 mmol) and the mixture was refluxed for 2 h.
The reaction was allowed to cool and the solvent removed under reduced I
pressure. A white crystalline solid formed on standing and was further 
purified by recrystallisation from ethanol/ diethyl ether (462 mg, 33 %), 
m.p. 135-137 °C; (Found: C, 72.25; H, 6.35; N, 9.9. Cj/HjgN202  requires C, 72.3;
H, 6.45; N, 9.9%); m/z (Found: [M + H]+, 283.1446. C17H 19N 2O2 requires 
283.1447); v^ax (Nujol) /cm -: 3284 (NH), 1658 (amide CO), 1627 (amide II),
1548,1245 & 1229; 8^  (200 MHz, C^HCb) 3.22 (2H, s, malonic CH2), 3.39 & 4.36 
(4H, 2 X s, benzyl CH2 's), 7.22-7.36 (lOH, m, aromatic CH's) & 7.74 (2H, br,
N H ’s); 8c (50.3 MHz, C^HCls) 43.47 (malonic CH2), 44.05 (benzyl CHz's), 127.96,
128.13, 129.17 (aromatic CH's), 138.28 (quaternary aromatics) & 167.89 (amide 
CO); m/z (Cl) 283 ([M + H]+, 100%).
Diethyl epoxymethylene malonate (121).
A flask containing diethyl malonate (1.6 g, 10 mmol), paraform aldehyde 
(0.6 g, 20 mmol), cupric acetate monohydrate (100 mg, 0.5 mmol), potassium 
acetate (100 mg, 1 mmol) and glacial acetic acid (5 cm^) was heated to 90 - 
100 °C in an oil bath until the mixture became clear, then for a further hour
%
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(approx. 2-3 h in all). Acetic acid and other volatile materials were distilled 
out at 90 - 100 °C. The residue was distilled again using a bunsen, to yield a 
greenish-yellow distillate of diethyl methylene malonate. The distillate was 
taken up in acetonitrile (6 cm^) and neutral alumina (9.0 g) and 10% sodium 
hypochlorite solution (15 cm^, 20 mmol) was added with stirring. A further 
equivalent (7.5 cm^) of hypochlorite solution was added an hour later. The 
reaction mixture was then allowed to stir at r.t. for 1 h, before being extracted 
with ether (3 x 50 cm^). The combined organic layers were washed with 5% 
sodium hydrogen carbonate solution, dried (MgSO^), filtered and evaporated 
under reduced pressure to yield a clear liquid which was purified by column 
chromatography on silica, eluting with 1% EtOH in CH2CI2 (660 mg, 35%); 
m/z (Found: [M + H]+ 189.0761. CgH^^Og requires 189.0763); (neat)/ cm-^ 
2986, 2942 (CH), 1747 (CO), 1468, 1448, 1377, 1353, 1319, 1241 & 1104; 6 ^ 
(200 MHz, C^HCls) 1.30 (6H, t,/7 .1 , CHg's), 3.21 (2H, s, epoxide CHg) & 4.27 (4H, 
q, /  7.1, malonate CHj's); 5^ (50.3 MHz, C^HClg) 14.39 (CHg’s), 51.46 (epoxide 
CH2), 55.98 (Quaternary C), 62.94 (malonate CH2*s) & 165.90 (CO's); m/z (Cl) 
189 ([M + H]+,100%).
Diethyl acetoxymethylhydroxymalonate (122).
Etc OEtOH
,CH
O
The epoxide (121) (940 mg, 5 mmol) was dissolved in glacial acetic acid 
(125 cm^) and to this was added sodium acetate (10.25 g, 125 mmol). This was 
heated to 90-100 °C for 4 h, then the solvent was removed under reduced 
pressure. The residue was dissolved in water (50 cm^) and the aqueous
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solution extracted with diethyl ether (3x50cm ^), The combined organic 
layers were w ashed w ith 5 % sodium  hydrogen carbonate solution 
(2 X100 cm^), dried (MgS0 4 ), filtered and the solvent removed to yield the 
product as a clear oil (781 mg, 63 %); m/z (Found: [M + H]+, 249.0970. C^oH^yOy 
requires 249.0974); v^ iax (neat)/ cm-i 3488 (br, OH), 2986 (CH), 1749 (CO), 1448, 
1371,1232 & 1161; (200 MHz, C^HCls) 1.31 (6H, t, /  7.1, ester CHg's), 2.08 (3H,
s, acetate CH3), 4.32 (4H, q , /  7.1, ester CHi's) & 4.59 (2H, s, CH2); 0^ (50.3 MHz, 
C^HCb) 14,41 (ester CHa’s), 21.09 (acetate CH3), 63.44 (ester CH2 's), 63.94 
(quaternary C), 65.75 (CH2), 168.56 & 170.83 (CO's); m/z (Cl) 249 ([M + H]+, 
14%) & 231 (100, [M + H - H20]+).
HIV-1 proteinase assays.
The assays are based upon the hydrolytic cleavage of the decapeptide 
Lys-Ala-Arg-V al-Nle-(N O2 )Phe-Glu-Ala-Nle-Gly-NH2 b e t w e e n  t h e  
norleucine and nitrophenylalanine residues which leads to a reduction in 
absorbance at 300 nm. The peptide was stored as a 10 mg ml"^ solution in 
water and 2 pi of this solution was added to 1 cm^ aliquot of assay buffer 
(100 mM NaOAc, 200 mM NaCl, ImM DTT at pH 5.6). The inhibitors to be 
tested were made up as 10 mM stock solutions in methanol and were used at 
concentrations over the range 1-100 pM. Methanol was added to a final 
concentration of 2 % in the assay mixture and the solution was allowed to 
thermally equilibrate to 37 °C before the reaction was initiated by the addition 
of 15 pL of enzyme. The enzyme was stored as a 0.993 pM solution in lOmM 
NaOAc containing 0.05% 2-mercaptoethanol, ImM EDTA, 20% glycerol and 
5% ethylene glycol.
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Anti-viral assays: acute infection of cells (C8166 cells / HlV-lllB)
This work was performed by D. Kinchington at St. Bartholomew's 
Hospital in London and is included here for completeness.
High titre virus stocks of the human immunodeficiency virus HIV-1 
(HTLV-III RF) were grown in H9 cells with RPMI 1640 (Flow laboratories) 
supplem ented with 10% fetal calf serum. Cell debris was removed by low 
speed centrifugation, and the supernatant stored at -70 °C until required. In a 
typical assay, C8166 T-lymphoblastoid CD4"  ^cells were incubated with TCIDso 
HIV-1 at 37 °C for 90 min and then washed three times with medium. Cell 
aliquots (2 x 10 )^ were suspended in 1.5 cm^ growth m edium in 6 cm^ tubes, 
and compounds in log dilutions [200 pM to 0.2 pM] were added immediately. 
The cells were then incubated at 37 °C in 5% CO2. After 72 h post-infection 
200 pi of supernatant was taken from each culture and assayed for H lV ^S 
using an antigen capture ELISA which recognises all the core proteins equally 
(Coulter Electronics, Luton, UK). The following controls were used: 
supernatants taken from uninfected and infected cells, infected cells treated 
with Ro-31-8959 (28) (Roche Products UK Ltd), AZT (1) (Roche Products UK, 
Ltd) and ddC (4) (Roche Products UK Ltd). The activities of 8959, AZT and 
ddC in infected cells each gave an IC50 of 3, 20 and 200 nM respectively. The 
ELISA plates were read with a spectrophotometer. Compounds were tested in 
duplicate at each concentration, and the data shown are the average of two 
assays.
To test for compound toxicity, aliquots of 2 x 10  ^ uninfected cells were 
cultured with the compounds in the same half log dilutions for 72 h. The 
cells were then washed with medium and resuspended in 200 pi of growth 
m edium  containing ^^C protein hydrolysate. After 12 h the cells were 
harvested and the "^^ C incorporation measured. Uninfected, untreated cells 
were used as controls.
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APPENDIX A
Publications
1. Camp, N. P., Perrey, D.A., Kinchington, D., Paul C. D. Hawkins and D. Gani, 
Bioorg. Med. Chem., in press.
. 'L
aAPPENDIX B 
I n  V i t r o  Assay Control Experiment
This was performed in an identical manner to the in vitro assay described in the f
3:experimental section, except the inhibitor used was Ro-31-8959 (28) (for which we I
thank Roche Ltd. for the supply of).
This gave an K{ value in this experiment of 7 nM (lit. value^oi of 0.12 nM).
